JP2021031404A - Composition for orally disintegrating tablet and production method thereof as well as orally disintegrating tablet using the same and production method thereof - Google Patents
Composition for orally disintegrating tablet and production method thereof as well as orally disintegrating tablet using the same and production method thereof Download PDFInfo
- Publication number
- JP2021031404A JP2021031404A JP2019149696A JP2019149696A JP2021031404A JP 2021031404 A JP2021031404 A JP 2021031404A JP 2019149696 A JP2019149696 A JP 2019149696A JP 2019149696 A JP2019149696 A JP 2019149696A JP 2021031404 A JP2021031404 A JP 2021031404A
- Authority
- JP
- Japan
- Prior art keywords
- orally disintegrating
- disintegrating tablet
- composition
- cellulose ether
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000006191 orally-disintegrating tablet Substances 0.000 title claims abstract description 197
- 239000000203 mixture Substances 0.000 title claims abstract description 107
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 34
- 229920003086 cellulose ether Polymers 0.000 claims abstract description 96
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims abstract description 73
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims abstract description 73
- 235000005487 catechin Nutrition 0.000 claims abstract description 73
- 229950001002 cianidanol Drugs 0.000 claims abstract description 73
- 239000003826 tablet Substances 0.000 claims abstract description 39
- 239000002994 raw material Substances 0.000 claims abstract description 36
- 239000000843 powder Substances 0.000 claims abstract description 18
- 238000007580 dry-mixing Methods 0.000 claims abstract description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 28
- 150000005846 sugar alcohols Chemical class 0.000 claims description 22
- 239000004480 active ingredient Substances 0.000 claims description 20
- 238000005469 granulation Methods 0.000 claims description 14
- 230000003179 granulation Effects 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 10
- 235000012438 extruded product Nutrition 0.000 claims description 9
- 239000007916 tablet composition Substances 0.000 claims description 9
- 229920013820 alkyl cellulose Polymers 0.000 claims description 7
- 238000010298 pulverizing process Methods 0.000 claims description 7
- 210000000214 mouth Anatomy 0.000 claims description 6
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 claims description 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 2
- 238000002844 melting Methods 0.000 claims 1
- 230000008018 melting Effects 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 33
- 238000001035 drying Methods 0.000 abstract description 5
- 230000008569 process Effects 0.000 abstract description 5
- 239000002245 particle Substances 0.000 description 40
- 238000001125 extrusion Methods 0.000 description 24
- -1 hydroxypropoxy group Chemical group 0.000 description 20
- 238000006073 displacement reaction Methods 0.000 description 19
- 229940024606 amino acid Drugs 0.000 description 14
- 235000001014 amino acid Nutrition 0.000 description 14
- 230000001186 cumulative effect Effects 0.000 description 14
- 239000000654 additive Substances 0.000 description 13
- 239000003814 drug Substances 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 11
- 239000008101 lactose Substances 0.000 description 11
- 239000004386 Erythritol Substances 0.000 description 10
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 10
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 description 10
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 10
- 229940009714 erythritol Drugs 0.000 description 10
- 235000019414 erythritol Nutrition 0.000 description 10
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 10
- 239000007864 aqueous solution Substances 0.000 description 9
- 229920000609 methyl cellulose Polymers 0.000 description 9
- 235000010981 methylcellulose Nutrition 0.000 description 9
- 239000001923 methylcellulose Substances 0.000 description 9
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 8
- 238000009826 distribution Methods 0.000 description 8
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 7
- 230000000996 additive effect Effects 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 6
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 6
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 5
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 5
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 5
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 description 5
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 5
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 5
- 239000011230 binding agent Substances 0.000 description 5
- 239000001913 cellulose Substances 0.000 description 5
- 239000007884 disintegrant Substances 0.000 description 5
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 5
- 235000012734 epicatechin Nutrition 0.000 description 5
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 description 5
- 235000013402 health food Nutrition 0.000 description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 5
- 238000000465 moulding Methods 0.000 description 5
- 239000004014 plasticizer Substances 0.000 description 5
- 244000269722 Thea sinensis Species 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 238000007906 compression Methods 0.000 description 4
- 230000006835 compression Effects 0.000 description 4
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
- 229960003943 hypromellose Drugs 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 238000004445 quantitative analysis Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 240000001307 Myosotis scorpioides Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- ANVAOWXLWRTKGA-XHGAXZNDSA-N all-trans-alpha-carotene Chemical compound CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1C(C)=CCCC1(C)C ANVAOWXLWRTKGA-XHGAXZNDSA-N 0.000 description 2
- 230000000954 anitussive effect Effects 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 239000003793 antidiarrheal agent Substances 0.000 description 2
- 229940125714 antidiarrheal agent Drugs 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 239000003430 antimalarial agent Substances 0.000 description 2
- 239000003907 antipyretic analgesic agent Substances 0.000 description 2
- 229940124584 antitussives Drugs 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229940125692 cardiovascular agent Drugs 0.000 description 2
- 239000002327 cardiovascular agent Substances 0.000 description 2
- 235000021466 carotenoid Nutrition 0.000 description 2
- 150000001747 carotenoids Chemical class 0.000 description 2
- 239000003576 central nervous system agent Substances 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229960003624 creatine Drugs 0.000 description 2
- 239000006046 creatine Substances 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 2
- 229960000991 ketoprofen Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 239000004089 psychotropic agent Substances 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 239000002151 riboflavin Substances 0.000 description 2
- 235000019192 riboflavin Nutrition 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000009747 swallowing Effects 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- AKNNEGZIBPJZJG-MSOLQXFVSA-N (-)-noscapine Chemical compound CN1CCC2=CC=3OCOC=3C(OC)=C2[C@@H]1[C@@H]1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-MSOLQXFVSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- JJVXHDTWVIPRBZ-VKHMYHEASA-N (2r)-2-[carboxy(methyl)amino]-3-sulfanylpropanoic acid Chemical compound OC(=O)N(C)[C@@H](CS)C(O)=O JJVXHDTWVIPRBZ-VKHMYHEASA-N 0.000 description 1
- YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 description 1
- KYBXNPIASYUWLN-WUCPZUCCSA-N (2s)-5-hydroxypyrrolidine-2-carboxylic acid Chemical compound OC1CC[C@@H](C(O)=O)N1 KYBXNPIASYUWLN-WUCPZUCCSA-N 0.000 description 1
- BAPRUDZDYCKSOQ-RITPCOANSA-N (2s,4r)-1-acetyl-4-hydroxypyrrolidine-2-carboxylic acid Chemical compound CC(=O)N1C[C@H](O)C[C@H]1C(O)=O BAPRUDZDYCKSOQ-RITPCOANSA-N 0.000 description 1
- DMASLKHVQRHNES-UPOGUZCLSA-N (3R)-beta,beta-caroten-3-ol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C DMASLKHVQRHNES-UPOGUZCLSA-N 0.000 description 1
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 1
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
- 239000001096 (4-ethenyl-1-azabicyclo[2.2.2]octan-7-yl)-(6-methoxyquinolin-4-yl)methanol hydrochloride Substances 0.000 description 1
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- NNKXWRRDHYTHFP-HZQSTTLBSA-N (r)-[(2s,4s,5r)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol;hydron;dichloride Chemical compound Cl.Cl.C([C@H]([C@H](C1)C=C)C2)CN1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 NNKXWRRDHYTHFP-HZQSTTLBSA-N 0.000 description 1
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 1
- FEDJGPQLLNQAIY-UHFFFAOYSA-N 2-[(6-oxo-1h-pyridazin-3-yl)oxy]acetic acid Chemical compound OC(=O)COC=1C=CC(=O)NN=1 FEDJGPQLLNQAIY-UHFFFAOYSA-N 0.000 description 1
- FIVHOHCAXWQPGC-UHFFFAOYSA-N 2-[2-(4-chlorophenoxy)acetyl]oxyethyl-dimethylazanium;chloride Chemical compound Cl.CN(C)CCOC(=O)COC1=CC=C(Cl)C=C1 FIVHOHCAXWQPGC-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 241000222518 Agaricus Species 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- KHOITXIGCFIULA-UHFFFAOYSA-N Alophen Chemical compound C1=CC(OC(=O)C)=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OC(C)=O)C=C1 KHOITXIGCFIULA-UHFFFAOYSA-N 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- AKJDEXBCRLOVTH-UHFFFAOYSA-N Carbetapentane citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C1(C(=O)OCCOCCN(CC)CC)CCCC1 AKJDEXBCRLOVTH-UHFFFAOYSA-N 0.000 description 1
- 240000003538 Chamaemelum nobile Species 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 239000004212 Cryptoxanthin Substances 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- WDJUZGPOPHTGOT-OAXVISGBSA-N Digitoxin Natural products O([C@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@H]1O)[C@H]1O[C@@H](C)[C@H](O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1 WDJUZGPOPHTGOT-OAXVISGBSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- PNMUAGGSDZXTHX-BYPYZUCNSA-N Gly-Gln Chemical compound NCC(=O)N[C@H](C(O)=O)CCC(N)=O PNMUAGGSDZXTHX-BYPYZUCNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 108010008488 Glycylglycine Proteins 0.000 description 1
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- ZXASMEUEMIIBDZ-UHFFFAOYSA-N Isoaminile citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CN(C)C(C)CC(C(C)C)(C#N)C1=CC=CC=C1 ZXASMEUEMIIBDZ-UHFFFAOYSA-N 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 240000000599 Lentinula edodes Species 0.000 description 1
- 240000000759 Lepidium meyenii Species 0.000 description 1
- 235000000421 Lepidium meyenii Nutrition 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- KSMRODHGGIIXDV-YFKPBYRVSA-N N-acetyl-L-glutamine Chemical compound CC(=O)N[C@H](C(O)=O)CCC(N)=O KSMRODHGGIIXDV-YFKPBYRVSA-N 0.000 description 1
- CAHKINHBCWCHCF-UHFFFAOYSA-N N-acetyltyrosine Chemical compound CC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 CAHKINHBCWCHCF-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- DRQXUCVJDCRJDB-UHFFFAOYSA-N Turanose Natural products OC1C(CO)OC(O)(CO)C1OC1C(O)C(O)C(O)C(CO)O1 DRQXUCVJDCRJDB-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 1
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- NTCYWJCEOILKNG-ROLPUNSJSA-N [(1r,2s)-1-hydroxy-1-phenylpropan-2-yl]-dimethylazanium;chloride Chemical compound Cl.CN(C)[C@@H](C)[C@H](O)C1=CC=CC=C1 NTCYWJCEOILKNG-ROLPUNSJSA-N 0.000 description 1
- HOBWAPHTEJGALG-JKCMADFCSA-N [(1r,5s)-8-methyl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;sulfate Chemical compound [O-]S([O-])(=O)=O.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1 HOBWAPHTEJGALG-JKCMADFCSA-N 0.000 description 1
- 229960005488 aceglutamide Drugs 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- XYAUIVRRMJYYHR-UHFFFAOYSA-N acetic acid;propane-1,2,3-triol Chemical compound CC(O)=O.OCC(O)CO XYAUIVRRMJYYHR-UHFFFAOYSA-N 0.000 description 1
- JUGOREOARAHOCO-UHFFFAOYSA-M acetylcholine chloride Chemical compound [Cl-].CC(=O)OCC[N+](C)(C)C JUGOREOARAHOCO-UHFFFAOYSA-M 0.000 description 1
- 229960004266 acetylcholine chloride Drugs 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229960001570 ademetionine Drugs 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 239000011795 alpha-carotene Substances 0.000 description 1
- 235000003903 alpha-carotene Nutrition 0.000 description 1
- ANVAOWXLWRTKGA-HLLMEWEMSA-N alpha-carotene Natural products C(=C\C=C\C=C(/C=C/C=C(\C=C\C=1C(C)(C)CCCC=1C)/C)\C)(\C=C\C=C(/C=C/[C@H]1C(C)=CCCC1(C)C)\C)/C ANVAOWXLWRTKGA-HLLMEWEMSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229960000852 alprenolol hydrochloride Drugs 0.000 description 1
- 229940093740 amino acid and derivative Drugs 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- SGRYPYWGNKJSDL-UHFFFAOYSA-N amlexanox Chemical compound NC1=C(C(O)=O)C=C2C(=O)C3=CC(C(C)C)=CC=C3OC2=N1 SGRYPYWGNKJSDL-UHFFFAOYSA-N 0.000 description 1
- 229960003731 amlexanox Drugs 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940124538 antidiuretic agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 235000013793 astaxanthin Nutrition 0.000 description 1
- 239000001168 astaxanthin Substances 0.000 description 1
- 229940022405 astaxanthin Drugs 0.000 description 1
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- 229960002028 atropine sulfate Drugs 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- IWVTXAGTHUECPN-ANBBSHPLSA-N bacampicillin hydrochloride Chemical compound [H+].[Cl-].C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)[C@H](C(S3)(C)C)C(=O)OC(C)OC(=O)OCC)=CC=CC=C1 IWVTXAGTHUECPN-ANBBSHPLSA-N 0.000 description 1
- 229960005412 bacampicillin hydrochloride Drugs 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 235000002360 beta-cryptoxanthin Nutrition 0.000 description 1
- DMASLKHVQRHNES-ITUXNECMSA-N beta-cryptoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CCCC2(C)C DMASLKHVQRHNES-ITUXNECMSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229960000503 bisacodyl Drugs 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000021329 brown rice Nutrition 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 239000001390 capsicum minimum Substances 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 229940098391 carbetapentane citrate Drugs 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 125000004403 catechin group Chemical group 0.000 description 1
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 1
- 229960005361 cefaclor Drugs 0.000 description 1
- 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229960004782 chlordiazepoxide Drugs 0.000 description 1
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 1
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 229960005168 croscarmellose Drugs 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 235000019244 cryptoxanthin Nutrition 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 229960001985 dextromethorphan Drugs 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- WDJUZGPOPHTGOT-XUDUSOBPSA-N digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 description 1
- 229960000648 digitoxin Drugs 0.000 description 1
- RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 description 1
- 229960005316 diltiazem hydrochloride Drugs 0.000 description 1
- 229960001056 dimemorfan Drugs 0.000 description 1
- ODJHDWLIOUGPPA-GUCVWDHMSA-N dimemorfan phosphate Chemical compound OP(O)(O)=O.C1C2=CC=C(C)C=C2[C@]23CCN(C)[C@H]1[C@H]2CCCC3 ODJHDWLIOUGPPA-GUCVWDHMSA-N 0.000 description 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- 229940120889 dipyrone Drugs 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 229940073563 dl- methylephedrine hydrochloride Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- SBNKFTQSBPKMBZ-UHFFFAOYSA-N ethenzamide Chemical compound CCOC1=CC=CC=C1C(N)=O SBNKFTQSBPKMBZ-UHFFFAOYSA-N 0.000 description 1
- 229960000514 ethenzamide Drugs 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 235000010944 ethyl methyl cellulose Nutrition 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 229940066493 expectorants Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
- 229960004369 flufenamic acid Drugs 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- 229950006836 fursultiamine Drugs 0.000 description 1
- JTLXCMOFVBXEKD-FOWTUZBSSA-N fursultiamine Chemical compound C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N JTLXCMOFVBXEKD-FOWTUZBSSA-N 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 239000004083 gastrointestinal agent Substances 0.000 description 1
- 229940127227 gastrointestinal drug Drugs 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 108010010147 glycylglutamine Proteins 0.000 description 1
- 229940043257 glycylglycine Drugs 0.000 description 1
- 229960002146 guaifenesin Drugs 0.000 description 1
- 238000007542 hardness measurement Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920013819 hydroxyethyl ethylcellulose Polymers 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- JGPMMRGNQUBGND-UHFFFAOYSA-N idebenone Chemical compound COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O JGPMMRGNQUBGND-UHFFFAOYSA-N 0.000 description 1
- 229960004135 idebenone Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229960004216 isoaminile Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 239000000905 isomalt Substances 0.000 description 1
- 235000010439 isomalt Nutrition 0.000 description 1
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 1
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 description 1
- 235000012902 lepidium meyenii Nutrition 0.000 description 1
- PGYPOBZJRVSMDS-UHFFFAOYSA-N loperamide hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 PGYPOBZJRVSMDS-UHFFFAOYSA-N 0.000 description 1
- 229960002983 loperamide hydrochloride Drugs 0.000 description 1
- 229960004391 lorazepam Drugs 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002160 maltose Drugs 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- 229960004963 mesalazine Drugs 0.000 description 1
- DJGAAPFSPWAYTJ-UHFFFAOYSA-M metamizole sodium Chemical compound [Na+].O=C1C(N(CS([O-])(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 DJGAAPFSPWAYTJ-UHFFFAOYSA-M 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- CMUHZRATLMUDJI-UHFFFAOYSA-N methyl 2h-pyridine-1-carboxylate Chemical compound COC(=O)N1CC=CC=C1 CMUHZRATLMUDJI-UHFFFAOYSA-N 0.000 description 1
- 229920003087 methylethyl cellulose Polymers 0.000 description 1
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 description 1
- 229940016409 methylsulfonylmethane Drugs 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229960002362 neostigmine Drugs 0.000 description 1
- ALWKGYPQUAPLQC-UHFFFAOYSA-N neostigmine Chemical compound CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 ALWKGYPQUAPLQC-UHFFFAOYSA-N 0.000 description 1
- KJONHKAYOJNZEC-UHFFFAOYSA-N nitrazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1 KJONHKAYOJNZEC-UHFFFAOYSA-N 0.000 description 1
- 229960001454 nitrazepam Drugs 0.000 description 1
- 229960004708 noscapine Drugs 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- VWMVAQHMFFZQGD-UHFFFAOYSA-N p-Hydroxybenzyl acetone Natural products CC(=O)CC1=CC=C(O)C=C1 VWMVAQHMFFZQGD-UHFFFAOYSA-N 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229940067631 phospholipid Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 229960002508 pindolol Drugs 0.000 description 1
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 1
- FFNMBRCFFADNAO-UHFFFAOYSA-N pirenzepine hydrochloride Chemical compound [H+].[H+].[Cl-].[Cl-].C1CN(C)CCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 FFNMBRCFFADNAO-UHFFFAOYSA-N 0.000 description 1
- 229960000293 pirenzepine hydrochloride Drugs 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- XXPDBLUZJRXNNZ-UHFFFAOYSA-N promethazine hydrochloride Chemical compound Cl.C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 XXPDBLUZJRXNNZ-UHFFFAOYSA-N 0.000 description 1
- 229960002244 promethazine hydrochloride Drugs 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 1
- 229960003908 pseudoephedrine Drugs 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 229960001811 quinine hydrochloride Drugs 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- NJGBTKGETPDVIK-UHFFFAOYSA-N raspberry ketone Chemical compound CC(=O)CCC1=CC=C(O)C=C1 NJGBTKGETPDVIK-UHFFFAOYSA-N 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 229940109850 royal jelly Drugs 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 229960001288 triamterene Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- RULSWEULPANCDV-PIXUTMIVSA-N turanose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](C(=O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RULSWEULPANCDV-PIXUTMIVSA-N 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
- 235000010930 zeaxanthin Nutrition 0.000 description 1
- 239000001775 zeaxanthin Substances 0.000 description 1
- 229940043269 zeaxanthin Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
本発明は、口腔内での優れた崩壊性を有する口腔内崩壊錠を製造するための口腔内崩壊錠用組成物及びその製造方法並びにこれを用いた口腔内崩壊錠及びその製造方法に関する。 The present invention relates to a composition for an orally disintegrating tablet for producing an orally disintegrating tablet having excellent disintegration property in the oral cavity, a method for producing the same, and an orally disintegrating tablet using the same and a method for producing the same.
医薬品製剤や健康食品の多くは、錠剤として経口投与により摂取される。錠剤は、通常、水とともに服用する。しかし、緊急を要する場合、重症患者が寝ながら服用する場合などは、錠剤を水とともに服用することが困難である。更に、嚥下機能が未熟な子供や嚥下機能が低下した老人にとっては、錠剤の嚥下が困難な場合があり、錠剤の服用性の改善が望まれている。 Many pharmaceutical preparations and health foods are taken orally as tablets. Tablets are usually taken with water. However, it is difficult to take tablets with water when there is an urgent need or when a critically ill patient takes the tablet while lying down. Further, it may be difficult for a child with an immature swallowing function or an elderly person with a deteriorated swallowing function to swallow the tablet, and improvement in the ease of taking the tablet is desired.
服用性が改善されたものとして、水無しで服用することができる口腔内崩壊錠が知られている。口腔内崩壊錠としては、薬物、水溶性高分子及び糖又は糖アルコールを含む薬物含有粒子と、マンニトール又はマンニトールとキシリトール、カルボキシメチルセルロース及び崩壊剤を含む噴霧乾燥粒子とを含有することを特徴とする口腔内崩壊錠が提案されている(特許文献1)。 Orally disintegrating tablets that can be taken without water are known as those with improved doability. The orally disintegrating tablet is characterized by containing drug-containing particles containing a drug, a water-soluble polymer and a sugar or a sugar alcohol, and spray-dried particles containing mannitol or mannitol and xylitol, carboxymethyl cellulose and a disintegrant. Orally disintegrating tablets have been proposed (Patent Document 1).
しかしながら、特許文献1に記載の口腔内崩壊錠は、その製造工程が、一方の原料を造粒することにより薬物含有粒子を得て、他方の原料を分散溶媒に分散させて噴霧乾燥して噴霧乾燥粒子を得て、次いで得られた薬物含有粒子及び噴霧乾燥粒子を混合及び打錠することを含み、錠剤化に至るまでの製造工程が煩雑である。 However, in the manufacturing process of the orally disintegrating tablet described in Patent Document 1, drug-containing particles are obtained by granulating one raw material, the other raw material is dispersed in a dispersion solvent, spray-dried and sprayed. The manufacturing process up to tableting is complicated, including obtaining dried particles and then mixing and tableting the obtained drug-containing particles and spray-dried particles.
また、口腔内崩壊錠は、適度な錠剤強度と優れた崩壊性とを兼ね備えた錠剤であるために、製剤設計が困難なものである。また、特許文献1で使用されているカルボキシメチルセルロースはイオン性の崩壊剤であるため、活性成分との相互作用が起きる場合がある。 Further, since the orally disintegrating tablet is a tablet having both appropriate tablet strength and excellent disintegrating property, it is difficult to design a formulation. Further, since carboxymethyl cellulose used in Patent Document 1 is an ionic disintegrant, an interaction with an active ingredient may occur.
そこで、本発明は、上記事情を鑑みて、複雑な工程を採用することなく製造することができ、適度な錠剤強度と優れた崩壊性とを有する口腔内崩壊錠を製造するための口腔内崩壊錠用組成物及びその製造方法を提供することを目的とする。また、本発明は、該口腔内崩壊錠及びその製造方法を提供することを目的とする。 Therefore, in view of the above circumstances, the present invention can be produced without adopting a complicated process, and the oral disintegration for producing an orally disintegrating tablet having appropriate tablet strength and excellent disintegration property. An object of the present invention is to provide a tablet composition and a method for producing the same. Another object of the present invention is to provide the orally disintegrating tablet and a method for producing the same.
本発明者らは、上記目的を達成するために鋭意検討した結果、驚くべきことに、水溶性セルロースエーテルと、カテキンと、糖とを含む原料を混合してなる組成物を用いることにより製造した口腔内崩壊錠は、適度な硬度を有しながら、口腔内において優れた崩壊性を示すことができることを見出した。 As a result of diligent studies to achieve the above object, the present inventors surprisingly produced the mixture by using a composition obtained by mixing a raw material containing water-soluble cellulose ether, catechin, and sugar. It has been found that the orally disintegrating tablet can exhibit excellent disintegration property in the oral cavity while having an appropriate hardness.
そして、遂に、上記の知見に基づいて、本発明の課題を解決し得るものとして、水溶性セルロースエーテルと、カテキンと、糖とを含む口腔内崩壊錠用組成物;該口腔内崩壊錠用組成物の製造方法;該口腔内崩壊錠用組成物の打錠物である口腔内崩壊錠;該口腔内崩壊錠の製造方法を創作することに成功した。本発明は、本発明者らによって初めて見出された知見及び成功例に基づいて完成されたものである。 Finally, based on the above findings, a composition for an orally disintegrating tablet containing a water-soluble cellulose ether, catechin, and a sugar; a composition for the orally disintegrating tablet, which can solve the problem of the present invention. Method for producing a product; an orally disintegrating tablet which is a tableted product of the composition for an orally disintegrating tablet; succeeded in creating a method for producing the orally disintegrating tablet. The present invention has been completed based on the findings and successful examples first discovered by the present inventors.
従って、本発明によれば、以下の態様の口腔内崩壊錠用組成物、口腔内崩壊錠用組成物の製造方法、口腔内崩壊錠及び口腔内崩壊錠の製造方法が提供される。
[1]水溶性セルロースエーテルと、カテキンと、糖とを含む口腔内崩壊錠用組成物。
[2]更に、糖アルコールを含む[1]に記載の口腔内崩壊錠用組成物。
[3]前記カテキンに対する前記水溶性セルロースエーテルの質量比(水溶性セルロースエーテル/カテキン)は1.0/1〜7.5/1である[1]又は[2]に記載の口腔内崩壊錠用組成物。
[4]更に、活性成分を含む[1]〜[3]のいずれかに記載の口腔内崩壊錠用組成物。
[5]前記水溶性セルロースエーテルが、アルキルセルロース、ヒドロキシアルキルセルロース及びヒドロキシアルキルアルキルセルロースからなる群から選ばれる少なくとも1種の水溶性セルロースエーテルである[1]〜[4]のいずれかに記載の口腔内崩壊錠用組成物。
[6][1]〜[5]のいずれかに記載の口腔内崩壊錠用組成物の打錠物である口腔内崩壊錠。
[7]水溶性セルロースエーテルと、カテキンと、糖とを含む粉末原料を乾式混合することにより、水溶性セルロースエーテルと、カテキンと、糖とを含む口腔内崩壊錠用組成物を得る工程を含む口腔内崩壊錠用組成物の製造方法。
[8]水溶性セルロースエーテルと、カテキンと、糖とを含む粉末原料に対して、水を含む水性原料を添加し造粒を行うことにより、水溶性セルロースエーテルと、カテキンと、糖とを含む口腔内崩壊錠用組成物を得る工程を含む口腔内崩壊錠用組成物の製造方法。
[9]水溶性セルロースエーテルと、カテキンとを含む粉末原料を加熱溶融押出することにより、水溶性セルロースエーテルと、カテキンとを含む押出物を得る工程と、前記押出物を粉砕することにより、粉砕物を得る工程と、前記粉砕物と、糖を含む原料とを混合することにより、水溶性セルロースエーテルと、カテキンと、糖とを含む口腔内崩壊錠用組成物を得る工程とを含む口腔内崩壊錠用組成物の製造方法。
[10]前記粉末原料は、更に活性成分を含む[7]〜[9]のいずれかに記載の口腔内崩壊錠用組成物の製造方法。
[11][7]〜[10]のいずれかに記載の口腔内崩壊錠用組成物を打錠することにより、口腔内崩壊錠を得る工程を含む口腔内崩壊錠の製造方法。
Therefore, according to the present invention, there are provided a composition for an orally disintegrating tablet, a method for producing a composition for an orally disintegrating tablet, and a method for producing an orally disintegrating tablet and an orally disintegrating tablet according to the following aspects.
[1] A composition for an orally disintegrating tablet containing a water-soluble cellulose ether, catechin, and sugar.
[2] The composition for an orally disintegrating tablet according to [1], which further contains a sugar alcohol.
[3] The orally disintegrating tablet according to [1] or [2], wherein the mass ratio of the water-soluble cellulose ether to the catechin (water-soluble cellulose ether / catechin) is 1.0 / 1 to 7.5 / 1. Composition for.
[4] The composition for an orally disintegrating tablet according to any one of [1] to [3], which further contains an active ingredient.
[5] The water-soluble cellulose ether according to any one of [1] to [4], wherein the water-soluble cellulose ether is at least one water-soluble cellulose ether selected from the group consisting of alkyl cellulose, hydroxyalkyl cellulose and hydroxyalkyl alkyl cellulose. Composition for orally disintegrating tablets.
[6] An orally disintegrating tablet which is a lock of the composition for an orally disintegrating tablet according to any one of [1] to [5].
[7] The present invention comprises a step of dry-mixing a powder raw material containing water-soluble cellulose ether, catechin, and sugar to obtain a composition for an orally disintegrating tablet containing water-soluble cellulose ether, catechin, and sugar. A method for producing a composition for an orally disintegrating tablet.
[8] A powder raw material containing water-soluble cellulose ether, catechin, and sugar is granulated by adding an aqueous raw material containing water to contain the water-soluble cellulose ether, catechin, and sugar. A method for producing an orally disintegrating tablet composition, which comprises a step of obtaining an orally disintegrating tablet composition.
[9] A step of obtaining an extrusion containing the water-soluble cellulose ether and catechin by heating and melt-extruding a powder raw material containing the water-soluble cellulose ether and catechin, and pulverization by pulverizing the extrusion. Intraoral including a step of obtaining a product and a step of obtaining a composition for an orally disintegrating tablet containing water-soluble cellulose ether, catechin, and sugar by mixing the pulverized product with a raw material containing sugar. A method for producing a composition for disintegrating tablets.
[10] The method for producing an orally disintegrating tablet composition according to any one of [7] to [9], wherein the powder raw material further contains an active ingredient.
[11] A method for producing an orally disintegrating tablet, which comprises a step of obtaining an orally disintegrating tablet by tableting the composition for an orally disintegrating tablet according to any one of [7] to [10].
本発明によれば、複雑な工程を採用することなく、十分な硬度を有し、かつ優れた崩壊性を示す口腔内崩壊錠を得ることができる。 According to the present invention, it is possible to obtain an orally disintegrating tablet having sufficient hardness and exhibiting excellent disintegration without adopting a complicated process.
以下、本発明の一態様である口腔内崩壊錠用組成物、口腔内崩壊錠用組成物の製造方法、口腔内崩壊錠及び口腔内崩壊錠の製造方法について詳細に説明するが、本発明はその目的を達成する限りにおいて種々の態様をとり得る。 Hereinafter, a composition for an orally disintegrating tablet, a method for producing a composition for an orally disintegrating tablet, and a method for producing an orally disintegrating tablet and an orally disintegrating tablet, which are one aspect of the present invention, will be described in detail. Various aspects can be taken as long as the purpose is achieved.
本明細書における各用語は、別段の定めがない限り、当業者により通常用いられている意味で使用され、不当に限定的な意味を有するものとして解釈されるべきではない。また、本明細書においてなされている推測及び理論は、本発明者らのこれまでの知見及び経験によってなされたものであることから、本発明はこのような推測及び理論のみによって拘泥されるものではない。 Unless otherwise specified, each term in the present specification is used in the meaning commonly used by those skilled in the art and should not be construed as having an unreasonably limited meaning. Moreover, since the guesses and theories made in the present specification are based on the knowledge and experience of the present inventors, the present invention is not bound by such guesses and theories alone. Absent.
「組成物」は、通常用いられている意味のものとして特に限定されないが、例えば、2種以上の成分が組み合わさってなる物である。「原料」は組成物を構成するための1種の成分又は2種以上の成分の組み合わせを意味する。
「口腔内崩壊錠」は、口腔内において口腔内の唾液のみ又は少量の水により短時間(概ね1分間以内、好ましくは30秒間以内)で崩壊する錠剤を意味する。
「及び/又は」との用語は、列記した複数の関連項目のいずれか1つ、又は2つ以上の任意の組み合わせ若しくは全ての組み合わせを意味する。
「含有量」は、濃度と同義であり、組成物の全体量に対する成分の量の割合を意味する。本明細書では、別段の定めがない限り、含有量の単位は「質量%(wt%)」を意味する。ただし、成分の含有量の総量は、100質量%を超えることはない。
数値範囲の「〜」は、その前後の数値を含む範囲であり、例えば、「0質量%〜100質量%」は、0質量%以上であり、かつ、100質量%以下である範囲を意味する。
「含む」は、含まれるものとして明示されている要素以外の要素を付加できることを意味する(「少なくとも含む」と同義である。)が、「からなる」及び「から本質的になる」を包含する。すなわち、「含む」は、明示されている要素及び任意の1種若しくは2種以上の要素を含み、明示されている要素からなり、又は明示されている要素から本質的になることを意味し得る。要素としては、成分、工程、条件、パラメーターなどの制限事項などが挙げられる。
The "composition" is not particularly limited as having a commonly used meaning, but is, for example, a combination of two or more kinds of components. "Raw material" means one component or a combination of two or more components to form a composition.
"Orally disintegrating tablet" means a tablet that disintegrates in the oral cavity with only saliva in the oral cavity or a small amount of water in a short time (generally within 1 minute, preferably within 30 seconds).
The term "and / or" means any one, or any combination of two or more, or all combinations of a plurality of related items listed.
"Content" is synonymous with concentration and means the ratio of the amount of the component to the total amount of the composition. In the present specification, unless otherwise specified, the unit of content means "mass% (wt%)". However, the total content of the components does not exceed 100% by mass.
"~" In the numerical range is a range including the numerical values before and after that, and for example, "0% by mass to 100% by mass" means a range of 0% by mass or more and 100% by mass or less. ..
"Including" means that elements other than those specified as being included can be added (synonymous with "at least including"), but includes "consisting of" and "essentially consisting of". To do. That is, "contains" can mean that it includes an explicit element and any one or more of the elements, consists of the explicit element, or essentially consists of the explicit element. .. Elements include restrictions such as components, processes, conditions, and parameters.
整数値の桁数と有効数字の桁数は一致する。例えば、1の有効数字は1桁であり、10の有効数字は2桁である。また、小数値は小数点以降の桁数と有効数字の桁数は一致する。例えば、0.1の有効数字は1桁であり、0.10の有効数字は2桁である。 The number of digits of an integer value and the number of digits of significant figures match. For example, 1 significant digit is 1 digit and 10 significant digit is 2 digits. In addition, the number of digits after the decimal point and the number of significant digits are the same for decimal numbers. For example, 0.1 significant digit is 1 digit and 0.10 significant digit is 2 digits.
<口腔内崩壊錠用組成物>
本発明の一態様の口腔内崩壊錠用組成物は、水溶性セルロースエーテルと、カテキンと、糖とを含む。
<Composition for orally disintegrating tablets>
The composition for an orally disintegrating tablet according to one aspect of the present invention contains a water-soluble cellulose ether, catechin, and sugar.
水溶性セルロースエーテルは、セルロースの水酸基の一部をエーテル化した非イオン性の高分子である。口腔内崩壊錠用組成物において、水溶性セルロースエーテルは、結合剤として機能するとともに、水和して膨潤することにより、崩壊剤としても機能する。 The water-soluble cellulose ether is a nonionic polymer in which a part of the hydroxyl groups of cellulose is etherified. In the composition for orally disintegrating tablets, the water-soluble cellulose ether functions as a binder and also functions as a disintegrant by hydrating and swelling.
水溶性セルロースエーテルは、水溶性を示すセルロースエーテルであればエーテルを構成する有機基については特に限定されないが、例えば、アルキルセルロース、ヒドロキシアルキルセルロース、ヒドロキシアルキルアルキルセルロースなどが挙げられる。 The water-soluble cellulose ether is not particularly limited as long as it is a water-soluble cellulose ether, and the organic group constituting the ether is not particularly limited, and examples thereof include alkyl cellulose, hydroxyalkyl cellulose, and hydroxyalkyl alkyl cellulose.
アルキルセルロースとしては、例えば、メチルセルロース、エチルセルロースなどが挙げられるが、易水溶性であるメチルセルロースが好ましい。 Examples of the alkyl cellulose include methyl cellulose and ethyl cellulose, but methyl cellulose, which is easily water-soluble, is preferable.
メチルセルロースにおけるメトキシ基含有量は、水への溶解性の観点から、好ましくは26.0質量%〜33.0質量%であり、より好ましくは27.5質量%〜31.5質量%である。メチルセルロースにおけるメトキシ基含有量は、第十七改正日本薬局方の「メチルセルロース」の項に記載の定量法によって測定される値である。 The methoxy group content in methylcellulose is preferably 26.0% by mass to 33.0% by mass, and more preferably 27.5% by mass to 31.5% by mass from the viewpoint of solubility in water. The methoxy group content in methylcellulose is a value measured by the quantitative method described in the section "Methylcellulose" of the 17th revised Japanese Pharmacopoeia.
ヒドロキシアルキルセルロースとしては、例えば、ヒドロキシプロピルセルロース、ヒドロキシエチルセルロースなどが挙げられるが、溶解性の観点からヒドロキシプロピルセルロースが好ましい。 Examples of the hydroxyalkyl cellulose include hydroxypropyl cellulose and hydroxyethyl cellulose, but hydroxypropyl cellulose is preferable from the viewpoint of solubility.
ヒドロキシプロピルセルロースにおけるヒドロキシプロポキシ基含有量は、溶解性の観点から、好ましくは53.4質量%〜77.5質量%であり、より好ましくは60.0質量%〜70.0質量%である。ヒドロキシプロピルセルロースにおけるヒドロキシプロポキシ基含有量は、第十七改正日本薬局方の「ヒドロキシプロピルセルロース」の項に記載の定量法によって測定される値である。 The hydroxypropoxy group content in hydroxypropyl cellulose is preferably 53.4% by mass to 77.5% by mass, and more preferably 60.0% by mass to 70.0% by mass from the viewpoint of solubility. The hydroxypropoxy group content in hydroxypropyl cellulose is a value measured by the quantitative method described in the section "Hydroxypropyl cellulose" of the 17th revised Japanese Pharmacopoeia.
ヒドロキシアルキルアルキルセルロースとしては、例えば、ヒプロメロース(ヒドロキシプロピルメチルセルロース;以下、「HPMC」とも記載する。)、ヒドロキシエチルメチルセルロース、ヒドロキシエチルエチルセルロースなどが挙げられるが、成形性及び崩壊性の観点から、HPMCが好ましい。 Examples of the hydroxyalkylalkyl cellulose include hypromellose (hydroxypropylmethyl cellulose; hereinafter, also referred to as “HPMC”), hydroxyethyl methyl cellulose, hydroxyethyl ethyl cellulose and the like, and HPMC is used from the viewpoint of moldability and disintegration. preferable.
HPMCにおけるメトキシ基含有量は、水への溶解性の観点から、好ましくは16.5質量%〜30.0質量%であり、より好ましくは19.0質量%〜30.0質量%であり、更に好ましくは19.0質量%〜29.0質量%である。また、HPMCにおけるヒドロキシプロポキシ基含有量は、水への溶解性の観点から、好ましくは3.0質量%〜32.0質量%であり、より好ましくは3.0質量%〜12.0質量%であり、更に好ましくは4.0質量%〜12.0質量%である。HPMCにおけるヒドロキシプロポキシ基含有量及びメトキシ基含有量は、第十七改正日本薬局方の「ヒプロメロース」の項に記載の定量法によって測定される値である。 The methoxy group content in HPMC is preferably 16.5% by mass to 30.0% by mass, more preferably 19.0% by mass to 30.0% by mass, from the viewpoint of solubility in water. More preferably, it is 19.0% by mass to 29.0% by mass. The hydroxypropoxy group content in HPMC is preferably 3.0% by mass to 32.0% by mass, more preferably 3.0% by mass to 12.0% by mass, from the viewpoint of solubility in water. It is more preferably 4.0% by mass to 12.0% by mass. The hydroxypropoxy group content and the methoxy group content in HPMC are values measured by the quantitative method described in the section "Hypromellose" of the 17th revised Japanese Pharmacopoeia.
水溶性セルロースエーテルにおける平均粒子径は、口腔内崩壊錠における硬度及び崩壊性の観点から、好ましくは50μm以上であり、より好ましくは55μm〜500μmであり、更に好ましくは60μm〜300μmである。水溶性セルロースエーテルにおける平均粒子径は、後述する実施例に記載があるとおりの方法によって測定される値(体積基準の累積粒度分布曲線の50%累積値)である。 The average particle size of the water-soluble cellulose ether is preferably 50 μm or more, more preferably 55 μm to 500 μm, and further preferably 60 μm to 300 μm from the viewpoint of hardness and disintegration property of the orally disintegrating tablet. The average particle size of the water-soluble cellulose ether is a value measured by a method as described in Examples described later (50% cumulative value of the volume-based cumulative particle size distribution curve).
水溶性セルロースエーテルの2質量%水溶液の20℃における粘度は、口腔内崩壊錠における硬度の観点から、好ましくは1.0mPa・s〜150,000mPa・sであり、より好ましくは2.0mPa・s〜120,000mPa・sであり、更に好ましくは2.5mPa・s〜6,000mPa・sである。水溶性セルロースエーテルの2質量%水溶液の20℃における粘度は、後述する実施例に記載があるとおりの方法によって測定される値である。 The viscosity of the 2% by mass aqueous solution of the water-soluble cellulose ether at 20 ° C. is preferably 1.0 mPa · s to 150,000 mPa · s, more preferably 2.0 mPa · s, from the viewpoint of the hardness of the orally disintegrating tablet. It is ~ 120,000 mPa · s, more preferably 2.5 mPa · s ~ 6,000 mPa · s. The viscosity of a 2% by mass aqueous solution of water-soluble cellulose ether at 20 ° C. is a value measured by a method as described in Examples described later.
水溶性セルロースエーテルは、上記に挙げたものなどの1種を単独で用いてもよいし、2種以上を併用して用いてもよい。水溶性セルロースエーテルは、市販のものを用いてもよいし、公知の方法により製造したものを用いてもよい。 As the water-soluble cellulose ether, one type such as those listed above may be used alone, or two or more types may be used in combination. As the water-soluble cellulose ether, a commercially available one may be used, or one produced by a known method may be used.
カテキンは、通常知られているとおりの、ポリフェノールの一種であり、チャ(茶)抽出物であれば特に限定されない。また、カテキンには、エピカテキン及びエピガロカテキンに加えて、ガレード基を有するエピガロカテキンガレード及びエピカテキンガレードが含まれる。 Catechin is a kind of polyphenol as is generally known, and is not particularly limited as long as it is a tea extract. In addition to epicatechin and epigallocatechin, catechin includes epigallocatechin galley and epicatechin galade having a garade group.
カテキンは、エピカテキン、エピガロカテキン、エピガロカテキンガレード及びエピカテキンガレードのいずれか2種、3種又は4種全てを含むものであることが好ましい。 The catechin preferably contains any two, three or four of epicatechin, epigallocatechin, epigallocatechin galley and epicatechin galade.
カテキンは、単独で用いてもよいし、2種類以上を併用して用いてもよい。カテキンは、市販のものを用いてもよいし、茶葉から常法に従って抽出して得られたものを用いてもよい。 The catechin may be used alone or in combination of two or more. As the catechin, a commercially available one may be used, or one obtained by extracting from tea leaves according to a conventional method may be used.
カテキンは、本発明者らが見出した知見によれば、水の存在下において、水溶性セルロースエーテルとともに不溶性の膨潤物を形成する。更に形成された不溶性の膨潤物は、口腔内崩壊錠用組成物における崩壊性に寄与する。 According to the findings found by the present inventors, catechin forms an insoluble swelling together with water-soluble cellulose ether in the presence of water. Further formed insoluble swelling contributes to disintegration in the orally disintegrating tablet composition.
本発明者らが見出した知見によれば、カテキンに対する水溶性セルロースエーテルの質量比(水溶性セルロースエーテル/カテキン)が大きい口腔内崩壊錠用組成物を用いることにより、硬度及び崩壊性に優れる口腔内崩壊錠が得られる傾向にある。そこで、カテキンに対する水溶性セルロースエーテルの質量比(水溶性セルロースエーテル/カテキン)は、水溶性セルロースエーテル及びカテキンによる不溶体の形成の観点から、好ましくは0.5/1〜7.5/1であり、より好ましくは1.0/1〜7.5/1であり、更に好ましくは1.0/1〜5.0/1である。 According to the findings found by the present inventors, by using a composition for an orally disintegrating tablet having a large mass ratio of water-soluble cellulose ether to catechin (water-soluble cellulose ether / catechin), the oral cavity is excellent in hardness and disintegration property. Internally disintegrating tablets tend to be obtained. Therefore, the mass ratio of the water-soluble cellulose ether to catechin (water-soluble cellulose ether / catechin) is preferably 0.5 / 1 to 7.5 / 1 from the viewpoint of forming an insoluble matter by the water-soluble cellulose ether and catechin. Yes, more preferably 1.0 / 1 to 7.5 / 1, and even more preferably 1.0 / 1 to 5.0 / 1.
水溶性セルロースエーテル及びカテキンの各含有量は、得られる口腔内崩壊錠の硬度及び崩壊性の観点から、水溶性セルロースエーテルの含有量は1.0質量%〜10質量%が好ましく、1.5質量%〜5.0質量がより好ましく;及び/又は、カテキンの含有量は0.1質量%〜10質量%が好ましく、0.5質量%〜5.0質量%がより好ましい。 The content of each of the water-soluble cellulose ether and catechin is preferably 1.0% by mass to 10% by mass, preferably 1.5% by mass, from the viewpoint of the hardness and disintegration of the obtained orally disintegrating tablet. The mass% to 5.0% by mass is more preferable; and / or the content of catechin is preferably 0.1% by mass to 10% by mass, more preferably 0.5% by mass to 5.0% by mass.
糖は、口腔内崩壊錠内部への導水を促進する媒体として機能する。
糖としては、例えば、乳糖、マルトース、ショ糖、プルラン、トレハロース、イソマルトース、ツラノース、セロビオースなどが挙げられるが、易水溶性の観点から単糖及び二糖であることが好ましい。糖の平均粒子径は、口腔内崩壊錠における硬度及び崩壊性の観点から、好ましくは5μm〜100μmであり、より好ましくは10μm〜50μmである。糖の平均粒子径は、後述する実施例に記載の方法によって測定される値(体積基準の累積粒度分布曲線の50%累積値)である。
Sugar functions as a medium that promotes water conduction into the orally disintegrating tablet.
Examples of the sugar include lactose, maltose, sucrose, pullulan, trehalose, isomaltose, turanose, cellobiose and the like, but monosaccharides and disaccharides are preferable from the viewpoint of water solubility. The average particle size of the sugar is preferably 5 μm to 100 μm, more preferably 10 μm to 50 μm, from the viewpoint of hardness and disintegration property of the orally disintegrating tablet. The average particle size of the sugar is a value measured by the method described in Examples described later (50% cumulative value of the volume-based cumulative particle size distribution curve).
口腔内崩壊錠用組成物における糖の含有量は、口腔内崩壊錠における導水性の観点から、水溶性セルロースエーテル及びカテキンの総質量100質量部に対して、好ましくは500質量部〜2,500質量部であり、より好ましくは800質量部〜2,200質量部である。 The sugar content in the composition for orally disintegrating tablets is preferably 500 parts by mass to 2,500 parts by mass with respect to 100 parts by mass of the total mass of the water-soluble cellulose ether and catechin from the viewpoint of water conductivity in the orally disintegrating tablets. It is by mass, more preferably 800 parts by mass to 2,200 parts by mass.
糖は、上記したものなどの1種を単独で用いてもよいし、2種以上を併用して用いてもよい。また、糖は、市販のものを用いることができる。 As the sugar, one kind such as the above-mentioned one may be used alone, or two or more kinds may be used in combination. In addition, commercially available sugar can be used.
口腔内崩壊錠用組成物は、更に糖アルコールを含むことが好ましい。口腔内崩壊錠用組成物が糖アルコールを含む場合、得られる口腔内崩壊錠における導水性が高まり、口腔内崩壊錠の崩壊性を向上させることができる。 The composition for orally disintegrating tablets preferably further contains a sugar alcohol. When the composition for an orally disintegrating tablet contains a sugar alcohol, the water conductivity of the obtained orally disintegrating tablet is enhanced, and the disintegration property of the orally disintegrating tablet can be improved.
糖アルコールとしては、例えば、エリスリトール、D/L(−/+)−マンニトール、キシリトール、イソマルト、ソルビトールなどが挙げられる。糖アルコールの平均粒子径は、口腔内崩壊錠における硬度及び崩壊性の観点から、好ましくは5μm〜500μmであり、より好ましくは10μm〜100μmである。糖アルコールの平均粒子径は、後述する実施例に記載の方法によって測定される値(体積基準の累積粒度分布曲線の50%累積値)である。 Examples of sugar alcohols include erythritol, D / L (− / +) -mannitol, xylitol, isomalt, sorbitol and the like. The average particle size of the sugar alcohol is preferably 5 μm to 500 μm, more preferably 10 μm to 100 μm, from the viewpoint of hardness and disintegration property of the orally disintegrating tablet. The average particle size of the sugar alcohol is a value measured by the method described in Examples described later (50% cumulative value of the volume-based cumulative particle size distribution curve).
口腔内崩壊錠用組成物における糖アルコールの含有量は、口腔内崩壊錠における崩壊性の観点から、水溶性セルロースエーテル及びカテキンの総質量100質量部に対して、好ましくは200質量部〜2,000質量部、より好ましくは300質量部〜1,600質量部である。 The content of sugar alcohol in the composition for orally disintegrating tablets is preferably 200 parts by mass to 2, with respect to 100 parts by mass of the total mass of the water-soluble cellulose ether and catechin from the viewpoint of disintegration in the orally disintegrating tablets. It is 000 parts by mass, more preferably 300 parts by mass to 1,600 parts by mass.
糖アルコールは、上記したものなどの1種を単独で用いてもよいし、2種以上を併用して用いてもよい。また、糖アルコールは、市販のものを用いることができる。 As the sugar alcohol, one kind such as the above-mentioned one may be used alone, or two or more kinds may be used in combination. Further, as the sugar alcohol, a commercially available one can be used.
口腔内崩壊錠用組成物は添加物を含むことができ、例えば、口腔内崩壊錠を通常製造するために使用される添加物を含むことができる。このような添加物としては、例えば、滑沢剤、矯味剤、香料剤の他、安定化剤、流動化剤、着色剤、清涼剤、防腐剤、キレート剤、pH調整剤、酸化防止剤、増粘剤などが挙げられる。添加物の使用量は、本発明の課題の解決を妨げない限り特に限定されず、適宜設定され得る。添加物のいくつかについて以下に列挙するが、これらはあくまでも例示であり、限定されるものではない。 The composition for an orally disintegrating tablet can contain an additive, for example, an additive usually used for producing an orally disintegrating tablet. Such additives include, for example, lubricants, flavoring agents, fragrances, stabilizers, fluidizing agents, coloring agents, cooling agents, preservatives, chelating agents, pH adjusters, antioxidants, etc. Examples include thickeners. The amount of the additive used is not particularly limited as long as it does not interfere with the solution of the problem of the present invention, and can be set as appropriate. Some of the additives are listed below, but these are examples only and are not limited.
滑沢剤としては、例えば、ステアリン酸マグネシウム、ステアリン酸カルシウム、タルク、フマル酸ステアリルナトリウム、ショ糖脂肪酸エステルなどが挙げられる。矯味剤としては、例えば、クエン酸、酒石酸、リンゴ酸などが挙げられる。香料剤としては、例えば、メントール、ハッカ油、バニリンなどが挙げられる。 Examples of the lubricant include magnesium stearate, calcium stearate, talc, sodium stearyl fumarate, and sucrose fatty acid ester. Examples of the flavoring agent include citric acid, tartaric acid, malic acid and the like. Examples of the fragrance include menthol, peppermint oil, vanillin and the like.
また、口腔内崩壊錠用組成物は、本発明の課題解決を妨げない限り、上記の水溶性セルロースエーテル、カテキン、糖に加えて、他の任意の崩壊剤、結合剤及び/又は賦形剤を含んでもよい。崩壊剤としては、例えば、低置換度ヒドロキシプロピルセルロース、コーンスターチ、部分アルファー化デンプン、カルボキシメチルスターチナトリウム、クロスカルメロース、クロスカルメロースナトリウム、結晶セルロース、クロスポビドンなどが挙げられる。結合剤としては、例えば、ポリビニルピロリドン、ポリビニルアルコールなどが挙げられる。賦形剤としては、例えば、結晶セルロース、粉末セルロース、リン酸カルシウム、硫酸カルシウムなどが挙げられる。 In addition to the above-mentioned water-soluble cellulose ether, catechin, and sugar, the composition for orally disintegrating tablets may contain any other disintegrant, binder, and / or excipient, as long as it does not interfere with the solution of the problem of the present invention. May include. Examples of the disintegrant include low-degree-of-substitution hydroxypropyl cellulose, corn starch, partially pregelatinized starch, sodium carboxymethyl starch, croscarmellose, croscarmellose sodium, crystalline cellulose, crospovidone and the like. Examples of the binder include polyvinylpyrrolidone, polyvinyl alcohol and the like. Examples of the excipient include crystalline cellulose, powdered cellulose, calcium phosphate, calcium sulfate and the like.
例えば、造粒工程及び加熱溶融押出工程を採用する場合は、採用する製造工程に応じて、溶媒、可塑剤、界面活性剤などを添加物として利用できる。 For example, when the granulation step and the heat melt extrusion step are adopted, a solvent, a plasticizer, a surfactant and the like can be used as additives depending on the manufacturing process to be adopted.
溶媒としては、例えば、精製水などの水、エタノール、イソプロパノールなどの炭素数1〜3の低級アルコールなどが挙げられる。可塑剤としては、例えば、アセトン、セチルアルコール、ステアリルアルコールなどの好ましくは炭素数10〜20の高級アルコール、グリセリンなどの好ましくは2〜6価の多価アルコール、ビーズワックス、クエン酸トリエチル、ポリエチレングリコール又はプロピレングリコール糖のアルキレングリコール、トリアセチン、ジブチルセバセート、グイセリンモノステアレート、モノグリセリンアセテートなどが挙げられる。界面活性剤としては、例えば、ラウリル硫酸ナトリウムなどの陰イオン性界面活性剤、ジグリセリド、ポロクサマー、ポリオキシエチレンソルビタン脂肪酸エステル(ツイン20、60、80)、グリセリン脂肪酸エステル、プロピレングリコール脂肪酸エステルなどの非イオン性界面活性剤、レシチン、タウロコール酸ナトリウムなどの天然界面活性剤などが挙げられる。 Examples of the solvent include water such as purified water and lower alcohols having 1 to 3 carbon atoms such as ethanol and isopropanol. Examples of the plasticizer include higher alcohols having 10 to 20 carbon atoms such as acetone, cetyl alcohol and stearyl alcohol, preferably polyhydric alcohols having 2 to 6 valences such as glycerin, bead wax, triethyl citrate and polyethylene glycol. Alternatively, alkylene glycol, triacetin, dibutyl sevasate, guiserine monostearate, monoglycerine acetate and the like of propylene glycol sugar can be mentioned. Examples of the surfactant include anionic surfactants such as sodium lauryl sulfate, diglycerides, porox summer, polyoxyethylene sorbitan fatty acid esters (twin 20, 60, 80), glycerin fatty acid esters, propylene glycol fatty acid esters and the like. Examples include ionic surfactants, natural surfactants such as lecithin and sodium taurocholate.
添加物は、上記したものなどの1種を単独で用いてもよいし、2種以上を併用して用いてもよい。また、添加物は、市販のものを用いることができる。 As the additive, one kind such as the above-mentioned one may be used alone, or two or more kinds may be used in combination. Further, as the additive, a commercially available one can be used.
口腔内崩壊錠用組成物における添加物の含有量は、本発明の課題解決を妨げない限り、特に限定されないが、口腔内崩壊錠における硬度及び崩壊性の観点から、水溶性セルロースエーテル及びカテキンの総質量100質量部に対して、好ましくは0質量部〜10,000質量部、より好ましくは50質量部〜1,000質量部である。 The content of the additive in the composition for orally disintegrating tablets is not particularly limited as long as it does not interfere with the solution of the problem of the present invention, but from the viewpoint of hardness and disintegration in the orally disintegrating tablets, water-soluble cellulose ether and catechin It is preferably 0 parts by mass to 10,000 parts by mass, and more preferably 50 parts by mass to 1,000 parts by mass with respect to 100 parts by mass of the total mass.
口腔内崩壊錠用組成物は、更に活性成分を含むことが好ましい。活性成分としては、経口投与可能な活性成分であれば特に限定されないが、例えば、医薬品に用いられる薬物、並びに栄養機能食品、特定保健用食品及び機能性表示食品などの健康食品に用いられる有効成分などが挙げられる。 The composition for orally disintegrating tablets preferably further contains an active ingredient. The active ingredient is not particularly limited as long as it is an orally administrable active ingredient, but is, for example, an active ingredient used in drugs used in pharmaceutical products and health foods such as nutritionally functional foods, foods for specified health uses and foods with functional claims. And so on.
医薬品に用いられる薬物としては、例えば、中枢神経系薬物、循環器系薬物、呼吸器系薬物、消化器系薬物、抗生物質、鎮咳・去たん剤、抗ヒスタミン剤、解熱鎮痛消炎剤、利尿剤、自律神経作用薬、抗マラリア剤、止潟剤、向精神剤、ビタミン類及びその誘導体などが挙げられる。 Drugs used in pharmaceuticals include, for example, central nervous system drugs, cardiovascular drugs, respiratory drugs, digestive system drugs, antibiotics, antitussive / expectorant drugs, antihistamines, antipyretic analgesic and anti-inflammatory agents, diuretics, and autonomy. Examples thereof include neuroactive agents, antimalarial agents, antidiarrheal agents, psychotropic agents, vitamins and derivatives thereof.
中枢神経系薬物としては、例えば、ジアゼパム、イデベノン、ナプロキセン、ピロキシカム、インドメタシン、スリンダック、ロラゼパム、ニトラゼパム、フェニトイン、アセトアミノフェン、エテンザミド、ケトプロフェン及びクロルジアゼポキシドなどが挙げられる。 Central nervous system drugs include, for example, diazepam, idebenone, naproxen, piroxicam, indomethacin, slindac, lorazepam, nitrazepam, phenytoin, acetaminophen, ethenzamide, ketoprofen and chlordiazepoxide.
循環器系薬物としては、例えば、モルシドミン、ビンポセチン、プロプラノロール、メチルドパ、ジピリダモール、フロセミド、トリアムテレン、ニフェジビン、アテノロール、スピロノラクトン、メトプロロール、ピンドロール、カプトプリル、硝酸イソソルビト、塩酸デラプリル、塩酸メクロフェノキサート、塩酸ジルチアゼム、塩酸エチレフリン、ジギトキシン及び塩酸アルプレノロールなどが挙げられる。 Cardiovascular drugs include, for example, morsidemin, vinposetin, propranolol, methyldopa, dipyridamole, furosemide, triamterene, nifedibin, atenolol, spironolactone, metoprolol, pindolol, captopril, isosorbit nitrate, derapril hydrochloride, meclophenoxate hydrochloride, diltiazem hydrochloride Examples thereof include etilefurin hydrochloride, digitoxin and alprenolol hydrochloride.
呼吸器系薬物としては、例えば、アムレキサノクス、デキストロメトルファン、テオフィリン、プソイドエフェドリン、サルブタモール及びグアイフェネシンなどが挙げられる。 Respiratory drugs include, for example, amlexanox, dextromethorphan, theophylline, pseudoephedrine, salbutamol and guaifenesin.
消化器系薬物としては、例えば、2−[〔3−メチル−4−(2,2,2−トリフルオロエトキシ)−2−ピリジル〕メチルスルフィニル]ベンゾイミダゾール及び5−メトキシ−2−〔(4−メトキシ−3,5−ジメチル−2−ピリジル)メチルスルフィニル〕ベンゾイミダゾールなどの抗潰瘍作用を有するベンゾイミダゾール系薬物、シメチジン、ラニチジン、塩酸ピレンゼピン、パンクレアチン、ビサコジル及び5−アミノサリチル酸などが挙げられる。 Examples of gastrointestinal drugs include 2-[[3-methyl-4- (2,2,2-trifluoroethoxy) -2-pyridyl] methylsulfinyl] benzimidazole and 5-methoxy-2-[(4). -Methoxy-3,5-dimethyl-2-pyridyl) methylsulfinyl] Benzimidazole drugs having anti-ulcer activity such as benzimidazole, cimetidine, ranitidine, pirenzepine hydrochloride, pancreatin, bisacodyl, 5-aminosalicylic acid and the like can be mentioned. ..
抗生物質としては、例えば、塩酸タランピシリン、塩酸バカンピシリン、セファクロル及びエリスロマイシンなどが挙げられる。 Examples of the antibiotic include tarampicillin hydrochloride, bacampicillin hydrochloride, cefaclor and erythromycin.
鎮咳・去たん剤としては、例えば、塩酸ノスカピン、クエン酸カルベタペンタン、クエン酸イソアミニル及びリン酸ジメモルファンなどが挙げられる。 Examples of antitussive / expectorant agents include noscapine hydrochloride, carbetapentane citrate, isoaminile citrate, dimemorfan phosphate and the like.
抗ヒスタミン剤としては、例えば、マレイン酸クロルフェニラミン、塩酸ジフェンヒドラミン及び塩酸プロメタジンなどが挙げられる。 Examples of the antihistamine include chlorpheniramine maleate, diphenhydramine hydrochloride and promethazine hydrochloride.
解熱鎮痛消炎剤としては、例えば、イブプロフェン、ジクロフェナクナトリウム、フルフェナム酸、スルピリン、アスピリン及びケトプロフェンなどが挙げられる。 Examples of antipyretic analgesic and anti-inflammatory agents include ibuprofen, diclofenac sodium, flufenamic acid, sulpyrine, aspirin and ketoprofen.
利尿剤としては、例えば、カフェインなどが挙げられる。 Examples of the diuretic include caffeine and the like.
自律神経作用薬としては、例えば、リン酸ジヒドロコデイン及びdl−塩酸メチルエフェドリン、硫酸アトロピン、塩化アセチルコリン、ネオスチグミンなどが挙げられる。 Examples of the autonomic nervous agent include dihydrocodein phosphate and dl-methylephedrine hydrochloride, atropine sulfate, acetylcholine chloride, neostigmine and the like.
抗マラリア剤としては、例えば、塩酸キニーネなどが挙げられる。止潟剤としては、例えば、塩酸ロペラミドなどが挙げられる。向精神剤としては、例えば、クロルプロマジンなどが挙げられる。 Examples of the antimalarial agent include quinine hydrochloride and the like. Examples of the antidiarrheal agent include loperamide hydrochloride and the like. Examples of the psychotropic agent include chlorpromazine and the like.
ビタミン類及びその誘導体としては、例えば、ビタミンA、ビタミンB1、フルスルチアミン、ビタミンB2、ビタミンB6、ビタミンB12、ビタミンC、ビタミンD、ビタミンE、ビタミンK、パントテン酸カルシウム及びトラネキサム酸などが挙げられる。 Examples of vitamins and their derivatives include vitamin A, vitamin B 1 , fursultiamine, vitamin B 2 , vitamin B 6 , vitamin B 12 , vitamin C, vitamin D, vitamin E, vitamin K, calcium pantothenate and tranexam. Examples include acids.
健康食品に用いられる有効成分としては、例えば、前記ビタミン類及びその誘導体、ミネラル、カロテノイド、アミノ酸及びその誘導体、植物エキス並びに健康食品素材などが挙げられる。 Examples of the active ingredient used in health foods include the vitamins and derivatives thereof, minerals, carotenoids, amino acids and derivatives thereof, plant extracts, and health food materials.
ミネラルとしては、例えば、カルシウム、マグネシウム、マンガン、亜鉛、鉄、銅、セレン、クロム、硫黄、ヨウ素などが挙げられる。 Examples of minerals include calcium, magnesium, manganese, zinc, iron, copper, selenium, chromium, sulfur and iodine.
カロテノイドとしては、例えば、β−カロチン、α−カロチン、ルテイン、クリプトキサンチン、ゼアキサンチン、リコペン、アスタキサンチン、マルチカロチンなどが挙げられる。 Examples of carotenoids include β-carotene, α-carotene, lutein, cryptoxanthin, zeaxanthin, lycopene, astaxanthin, and multicarotene.
アミノ酸としては、例えば、酸性アミノ酸、塩基性アミノ酸、中性アミノ酸及び酸性アミノ酸アミドなどが挙げられる。 Examples of amino acids include acidic amino acids, basic amino acids, neutral amino acids and acidic amino acid amides.
酸性アミノ酸としては、例えば、アスパラギン酸及びグルタミン酸などが挙げられる。塩基性アミノ酸としては、例えば、リシン、アルギニン及びヒスチジンなどが挙げられる。 Examples of acidic amino acids include aspartic acid and glutamic acid. Examples of basic amino acids include lysine, arginine and histidine.
中性アミノ酸としては、例えば、アラニン及びグリシンなどの直鎖状の脂肪族アミノ酸、バリン、ロイシン及びイソロイシンなどの分岐状の脂肪族アミノ酸、セリン及びトレオニンなどのヒドロキシアミノ酸、システイン及びメチオニンなどの含硫アミノ酸、フェニルアラニン及びチロシンなどの芳香族アミノ酸、トリプトファンなどの複素環式アミノ酸及びプロリンなどのイミノ酸などが挙げられる。 Examples of neutral amino acids include linear aliphatic amino acids such as alanine and glycine, branched aliphatic amino acids such as valine, leucine and isoleucine, hydroxyamino acids such as serine and threonine, and sulfurized compounds such as cysteine and methionine. Examples include amino acids, aromatic amino acids such as phenylalanine and tyrosine, heterocyclic amino acids such as tryptophan, and iminoic acid such as proline.
酸性アミノ酸アミドとしては、例えば、アスパラギン及びグルタミンなどが挙げられる。 Examples of the acidic amino acid amide include asparagine and glutamine.
アミノ酸誘導体としては、例えば、アセチルグルタミン、アセチルシステイン、カルボキシメチルシステイン、アセチルチロシン、アセチルヒドロキシプロリン、5−ヒドロキシプロリン、グルタチオン、クレアチン、S−アデノシルメチオニン、グリシルグリシン、グリシルグルタミン、ドーパ、アラニルグルタミン、カルニチン及びγ−アミノ酪酸などが挙げられる。 Examples of amino acid derivatives include acetylglutamine, acetylcysteine, carboxymethylcysteine, acetyltyrosine, acetylhydroxyproline, 5-hydroxyproline, glutathione, creatine, S-adenosylmethionine, glycylglycine, glycylglutamine, dopa, and ara. Examples include nilglutamine, carnitine and γ-aminobutyric acid.
植物エキスとしては、例えば、アロエ、プロポリス、アガリクス、高麗人参、イチョウ葉、ウコン、クルクミン、発芽玄米、椎茸菌糸体、甜茶、甘茶、メシマコブ、ごま、にんにく、マカ、冬虫夏草、カミツレ及びトウガラシなどが挙げられる。 Examples of plant extracts include aloe, propolis, agaricus, ginseng, ginkgo biloba, turmeric, curcumin, germinated brown rice, shiitake mushroom mycelium, sweet tea, sweet tea, caterpillar fungus, sesame, garlic, maca, caterpillar fungus, chamomile and capsicum. Be done.
健康食品素材としては、例えば、ローヤルゼリー、食物繊維、プロテイン、ビフィズス菌、乳酸菌、キトサン、酵母、グルコサミン、レシチン、ポリフェノール、動物魚介軟骨、スッポン、ラクトフェリン、シジミ、エイコサペンタエン酸、ゲルマニウム、酵素、クレアチン、カルニチン、クエン酸、ラズベリーケトン、コエンザイムQ10、メチルスルホニルメタン及びリン脂質結合大豆ペプチドなどが挙げられる。 Examples of health food materials include royal jelly, dietary fiber, protein, bifidobacteria, lactic acid bacteria, chitosan, yeast, glucosamine, lecithin, polyphenols, animal seafood cartilage, sponge, lactoferrin, shijimi, eikosapentaenoic acid, germanium, enzymes, creatine, etc. Examples thereof include carnithin, citric acid, raspberry ketone, coenzyme Q10, methylsulfonylmethane and phospholipid-bound soybean peptide.
活性成分の含有量は、所望の薬理作用又は機能性などに応じて適宜決定することができるが、例えば、口腔内崩壊錠の硬度及び崩壊性の観点から、水溶性セルロースエーテル及びカテキンの総質量100質量部に対して、好ましくは200質量部〜1,100質量部である。 The content of the active ingredient can be appropriately determined according to the desired pharmacological action or functionality, and for example, from the viewpoint of hardness and disintegration of the orally disintegrating tablet, the total mass of the water-soluble cellulose ether and catechin. It is preferably 200 parts by mass to 1,100 parts by mass with respect to 100 parts by mass.
活性成分は、上記したものなどの1種を単独で用いてもよいし、2種以上を併用して用いてもよい。また、活性成分は、市販のものを用いることができる。 As the active ingredient, one kind such as the above-mentioned one may be used alone, or two or more kinds may be used in combination. Further, as the active ingredient, a commercially available one can be used.
<口腔内崩壊錠用組成物の製造方法>
口腔内崩壊錠用組成物は、水溶性セルロースエーテルと、カテキンと、糖とを含み、かつ打錠工程に供することにより口腔内崩壊錠が得られるように製造される。口腔内崩壊錠用組成物の製造方法は特に限定されず、例えば、乾式混合、造粒、加熱溶融押出などの工程を含む方法などが挙げられる。
<Manufacturing method of composition for orally disintegrating tablets>
The composition for an orally disintegrating tablet contains water-soluble cellulose ether, catechin, and sugar, and is produced so that an orally disintegrating tablet can be obtained by subjecting it to a tableting step. The method for producing the composition for orally disintegrating tablets is not particularly limited, and examples thereof include methods including steps such as dry mixing, granulation, and heat melt extrusion.
[乾式混合]
乾式混合を採用する方法は、水溶性セルロースエーテルと、カテキンと、糖とを含む粉末原料を乾式混合することにより、水溶性セルロースエーテルと、カテキンと、糖とを含む口腔内崩壊錠用組成物を得る工程を含む。
[Dry mixing]
The method of adopting dry mixing is a composition for an orally disintegrating tablet containing water-soluble cellulose ether, catechin, and sugar by dry-mixing a powder raw material containing water-soluble cellulose ether, catechin, and sugar. Includes the step of obtaining.
乾式混合の方法は、特に限定されない。乾式混合に供する粉末原料は、糖アルコール及び任意の添加物を含んでもよい。粉末原料は、活性成分を含むことが好ましい。 The method of dry mixing is not particularly limited. The powder raw material to be subjected to dry mixing may contain a sugar alcohol and any additive. The powder raw material preferably contains an active ingredient.
乾式混合を採用する場合、口腔内崩壊錠用組成物によって製造される口腔内崩壊錠の崩壊性の観点から、平均粒子径が100μm以上である水溶性セルロースエーテルを用いることが好ましく、平均粒子径が100μm〜300μmである水溶性セルロースエーテルを用いることがより好ましい。口腔内崩壊錠用組成物は、このような平均粒子径を有する水溶性セルロースエーテルを含有することにより、打錠後においても、水溶性セルロースエーテルがある程度の大きさで口腔内崩壊錠に存在することができるため、より崩壊性に優れる。水溶性セルロースエーテルの平均粒子径は、後述する実施例に記載の方法によって測定される値(体積基準の累積粒度分布曲線の50%累積値)である。 When dry mixing is adopted, it is preferable to use a water-soluble cellulose ether having an average particle size of 100 μm or more, and an average particle size is preferable, from the viewpoint of disintegration of the orally disintegrating tablet produced by the composition for orally disintegrating tablets. It is more preferable to use a water-soluble cellulose ether having a size of 100 μm to 300 μm. By containing the water-soluble cellulose ether having such an average particle size in the composition for orally disintegrating tablets, the water-soluble cellulose ether is present in the orally disintegrating tablets in a certain size even after tableting. Because it can be used, it is more resistant to disintegration. The average particle size of the water-soluble cellulose ether is a value measured by the method described in Examples described later (50% cumulative value of the volume-based cumulative particle size distribution curve).
[造粒]
造粒を採用する方法は、水溶性セルロースエーテルと、カテキンと、糖とを含む粉末原料に対して、水を含む水性原料を添加して造粒を行うことにより、水溶性セルロースエーテルと、カテキンと、糖とを含む口腔内崩壊錠用組成物を得る工程を含む。
[Granulation]
The method of adopting granulation is to add a water-soluble raw material containing water to a powder raw material containing water-soluble cellulose ether, catechin, and sugar to perform granulation, thereby forming a water-soluble cellulose ether and catechin. A step of obtaining a composition for an orally disintegrating tablet containing sugar and sugar is included.
造粒は、造粒機を用いることにより行うことができる。造粒機としては、例えば、流動層造粒機、撹拌造粒機、転動流動層造粒機、噴霧乾燥造粒機などが挙げられるが、これらに限定されない。 Granulation can be performed by using a granulator. Examples of the granulator include, but are not limited to, a fluidized bed granulator, a stirring granulator, a rolling fluidized bed granulator, and a spray-drying granulator.
流動層造粒機を用いて造粒を行う場合、造粒の進行効率及び造粒物の品質の観点から、吸気温度は好ましくは50℃〜100℃であり;及び/又は、排気温度は好ましくは25℃〜80℃である。 When granulating is performed using a fluidized bed granulator, the intake temperature is preferably 50 ° C to 100 ° C; and / or the exhaust temperature is preferable from the viewpoint of the progress efficiency of granulation and the quality of the granulated product. Is 25 ° C to 80 ° C.
水性原料における水の含有量は特に限定されないが、好ましくは20質量%〜100質量%である。水性原料は結合剤の水溶液を含めてもよい。また、水性原料は成分の溶解性を高めるために炭素数1〜3の低級アルコールを含むことが好ましい。水性原料における炭素数1〜3の低級アルコールの含有量は、結合剤の溶解性の観点から、好ましくは10質量%〜80質量%である。また、粉末原料及び/又は水性原料は、任意に、糖アルコール及びその他の添加物を含み得る。粉末原料は、活性成分を含むことが好ましい。 The content of water in the aqueous raw material is not particularly limited, but is preferably 20% by mass to 100% by mass. The aqueous raw material may include an aqueous solution of the binder. Further, the aqueous raw material preferably contains a lower alcohol having 1 to 3 carbon atoms in order to enhance the solubility of the component. The content of the lower alcohol having 1 to 3 carbon atoms in the aqueous raw material is preferably 10% by mass to 80% by mass from the viewpoint of the solubility of the binder. In addition, the powder raw material and / or the aqueous raw material may optionally contain a sugar alcohol and other additives. The powder raw material preferably contains an active ingredient.
造粒物の平均粒子径は、口腔内崩壊錠用組成物によって製造される口腔内崩壊錠の硬度及び崩壊性の観点から、好ましくは120μm〜500μmであり、より好ましくは150μm〜250μmである。造粒物の平均粒子径は、後述する実施例に記載の方法によって測定される値(体積基準の累積粒度分布曲線の50%累積値)である。 The average particle size of the granulated product is preferably 120 μm to 500 μm, more preferably 150 μm to 250 μm, from the viewpoint of hardness and disintegration property of the orally disintegrating tablet produced by the composition for orally disintegrating tablets. The average particle size of the granulated product is a value measured by the method described in Examples described later (50% cumulative value of the volume-based cumulative particle size distribution curve).
造粒物は、乾燥処理に供することが好ましい。ただし、噴霧と乾燥とを同時に行うことができる流動層造粒機などを用いる場合はこの限りではない。造粒物の乾燥は、公知の方法、例えば、流動層乾燥機、棚団乾燥機などを用いて行うことができる。乾燥温度は特に限定されないが、好ましくは40℃〜80℃である。 The granulated product is preferably subjected to a drying treatment. However, this does not apply when a fluidized bed granulator or the like capable of spraying and drying at the same time is used. The granulated product can be dried by using a known method, for example, a fluidized bed dryer, a shelf dryer, or the like. The drying temperature is not particularly limited, but is preferably 40 ° C to 80 ° C.
造粒物の水分は、製剤の安定性の観点から、好ましくは5質量%以下であり、より好ましくは0.2質量%〜1質量%である。造粒物の水分は、後述する実施例に記載の方法により測定される。 From the viewpoint of the stability of the preparation, the water content of the granulated product is preferably 5% by mass or less, more preferably 0.2% by mass to 1% by mass. The water content of the granulated product is measured by the method described in Examples described later.
造粒により口腔内崩壊錠用組成物を製造する場合においては、生産性の観点から、2質量%水溶液の20℃における粘度が1.0mPa・s〜100mPa・sである水溶性セルロースエーテルを用いることが好ましく、2質量%水溶液の20℃における粘度が2.0mPa・s〜10.0mPa・sである水溶性セルロースエーテルを用いることがより好ましい。 When producing a composition for orally disintegrating tablets by granulation, a water-soluble cellulose ether having a viscosity of a 2% by mass aqueous solution at 20 ° C. of 1.0 mPa · s to 100 mPa · s is used from the viewpoint of productivity. It is preferable to use a water-soluble cellulose ether having a viscosity of a 2% by mass aqueous solution at 20 ° C. of 2.0 mPa · s to 10.0 mPa · s.
造粒を採用する方法により、水溶性セルロースエーテルと、カテキンと、糖とを含む造粒物を含む口腔内崩壊錠用組成物を得ることができる。 By a method that employs granulation, a composition for an orally disintegrating tablet containing a granulated product containing water-soluble cellulose ether, catechin, and sugar can be obtained.
[加熱溶融押出]
加熱溶融押出を採用する方法は、水溶性セルロースエーテルと、カテキンとを含む粉末原料を加熱溶融押出することにより、水溶性セルロースエーテルと、カテキンとを含む押出物を得る工程と、押出物を粉砕することにより、粉砕物を得る工程と、粉砕物と、糖を含む原料とを混合することにより、水溶性セルロースエーテルと、カテキンと、糖とを含む口腔内崩壊錠用組成物を得る工程とを含む。
[Heat melt extrusion]
The method of adopting heat melt extrusion is a step of obtaining an extrusion containing water-soluble cellulose ether and catechin by heat melt extrusion of a powder raw material containing water-soluble cellulose ether and catechin, and pulverizing the extrusion. A step of obtaining a pulverized product, and a step of mixing the pulverized product with a raw material containing sugar to obtain a composition for an orally disintegrating tablet containing water-soluble cellulose ether, catechin, and sugar. including.
加熱溶融押出は、加熱溶融押出機を用いて行うことができる。加熱溶融押出機としては、例えば、キャピログラフ(東洋精機社製)などの一軸ピストン型押出装置、「Nano−16」(ライストリッツ(Leistritz)社製)、「Mini Lab」(サーモフィッシャーサイエンティフィック(Thermo fisher Scientific)社製)及び「Pharma Lab」(サーモフィッシャーサイエンティフィック(Thermo fisher Scientific)社製)などの二軸スクリュー型押出装置などが挙げられる。 The heat melt extrusion can be performed using a heat melt extruder. Examples of the heat melt extruder include a uniaxial piston type extruder such as Capillograph (manufactured by Toyo Seiki Co., Ltd.), "Nano-16" (manufactured by Leistritz), and "Mini Lab" (Thermo Fisher Scientific). Biaxial screw type extruders such as (manufactured by Thermo Fisher Scientific) and "Pharma Lab" (manufactured by Thermo Fisher Scientific) and the like can be mentioned.
加熱溶融押出の条件は、使用する装置などによって適宜設定することができる。例えば、加熱溶融押出におけるバレル温度は、スクリューによる混錬押出性の観点から、好ましくは100℃〜220℃である。加熱溶融押出におけるスクリュー回転数は、生産性及び溶融物の安定性の観点から、好ましくは20rpm〜500rpmである。 The conditions for heat melt extrusion can be appropriately set depending on the equipment to be used and the like. For example, the barrel temperature in heat melt extrusion is preferably 100 ° C. to 220 ° C. from the viewpoint of kneading extrusion by a screw. The screw rotation speed in heat melt extrusion is preferably 20 rpm to 500 rpm from the viewpoint of productivity and stability of the melt.
加熱溶融押出に供する粉末原料は、水溶性セルロースエーテル及びカテキンを含めば特に限定されないが、例えば、任意に、可塑剤、界面活性剤などの添加物を添加してもよい。粉末原料は、活性成分を含むことが好ましい。可塑剤の使用量は、保存安定性の観点から、水溶性セルロースエーテル100質量部に対して、好ましくは30質量部以下である。界面活性剤の使用量は、保存安定性の観点から、水溶性セルロースエーテル100質量部に対して、好ましくは10質量部以下である。可塑剤及び界面活性剤の使用量の下限は特に限定されず、典型的には0質量部である。 The powder raw material to be subjected to heat melt extrusion is not particularly limited as long as it contains water-soluble cellulose ether and catechin, but for example, additives such as a plasticizer and a surfactant may be optionally added. The powder raw material preferably contains an active ingredient. From the viewpoint of storage stability, the amount of the plasticizer used is preferably 30 parts by mass or less with respect to 100 parts by mass of the water-soluble cellulose ether. From the viewpoint of storage stability, the amount of the surfactant used is preferably 10 parts by mass or less with respect to 100 parts by mass of the water-soluble cellulose ether. The lower limit of the amount of the plasticizer and the surfactant used is not particularly limited, and is typically 0 parts by mass.
加熱溶融押出を採用する方法により、水溶性セルロースエーテルと、カテキンとの混合性を乾式混合又は造粒を採用する方法に比べて高めることができ、結果として得られる口腔内崩壊錠の崩壊性を良好にすることができる。 By the method adopting heat melt extrusion, the mixing property of the water-soluble cellulose ether and catechin can be enhanced as compared with the method adopting dry mixing or granulation, and the disintegration property of the resulting orally disintegrating tablet can be improved. Can be good.
加熱溶融押出により得た押出物を粉砕することにより、粉砕物を得る。押出物は通常はストランド状の生成物であるため、押出物を用いて口腔内崩壊錠を製造するために粉砕工程を採用する。 A pulverized product is obtained by pulverizing the extruded product obtained by heat melt extrusion. Since the extruded product is usually a strand-like product, a pulverization step is adopted to produce an orally disintegrating tablet using the extruded product.
押出物の粉砕は特に限定されないが、例えば、粉砕機を用いて行うことができる。粉砕機としては、例えば、コーヒーミル、ハンマーミル、ピンミル、ジェットミルなどが挙げられる。粉砕機を用いることにより任意の粒子径に粉砕することができる。粉砕物の平均粒子径は、口腔内崩壊錠の硬度及び崩壊性、後段に使用する糖及び糖アルコールとの混合均一性の観点から、好ましくは50μm〜350μmであり、より好ましくは100μm〜200μmである。粉砕物の平均粒子径は、後述する実施例に記載の方法により測定される値(体積基準の累積粒度分布曲線の50%累積値)である。 The pulverization of the extruded product is not particularly limited, but can be performed using, for example, a pulverizer. Examples of the crusher include a coffee mill, a hammer mill, a pin mill, a jet mill and the like. It can be crushed to an arbitrary particle size by using a crusher. The average particle size of the pulverized product is preferably 50 μm to 350 μm, more preferably 100 μm to 200 μm, from the viewpoint of hardness and disintegration of the orally disintegrating tablet and mixing uniformity with sugar and sugar alcohol used in the subsequent stage. is there. The average particle size of the pulverized product is a value measured by the method described in Examples described later (50% cumulative value of the volume-based cumulative particle size distribution curve).
得られた粉砕物(粉砕された押出物)と、糖を含む原料とを混合することにより、水溶性セルロースエーテルと、カテキンと、糖とを含む口腔内崩壊錠用組成物を得る。糖を含む原料は、糖アルコールを含むことが好ましい。粉砕物と、糖を含む原料との混合は、均一な混合物が得られる限り、特に限定されない。 By mixing the obtained pulverized product (crushed extruded product) with a raw material containing sugar, a composition for an orally disintegrating tablet containing water-soluble cellulose ether, catechin, and sugar is obtained. The sugar-containing raw material preferably contains a sugar alcohol. The mixing of the pulverized product and the raw material containing sugar is not particularly limited as long as a uniform mixture can be obtained.
加熱溶融押出により、口腔内崩壊錠用組成物を製造する場合においては、生産性の観点から、2質量%水溶液の20℃における粘度が1.0mPa・s〜100mPa・sの水溶性セルロースエーテルを用いることが好ましく、2質量%水溶液の20℃における粘度が2.0mPa・s〜10.0mPa・sの水溶性セルロースエーテルを用いることがより好ましい。 In the case of producing a composition for orally disintegrating tablets by heat melt extrusion, from the viewpoint of productivity, a water-soluble cellulose ether having a viscosity of a 2% by mass aqueous solution at 20 ° C. of 1.0 mPa · s to 100 mPa · s is used. It is preferable to use, and it is more preferable to use a water-soluble cellulose ether having a viscosity of a 2% by mass aqueous solution at 20 ° C. of 2.0 mPa · s to 10.0 mPa · s.
加熱溶融押出を採用する方法により、水溶性セルロースエーテル及びカテキンを含む加熱溶融押出物と、糖とを含む口腔内崩壊錠用組成物を得ることができる。 By a method that employs heat melt extrusion, a composition for an orally disintegrating tablet containing a heat melt extrusion containing water-soluble cellulose ether and catechin and sugar can be obtained.
<口腔内崩壊錠>
口腔内崩壊錠用組成物を打錠することにより、口腔内崩壊錠が得られる。口腔内崩壊錠は、本発明の一態様である口腔内崩壊錠用組成物によって得られるものである限り、硬度、崩壊性などの物性については特に限定されない。
<Orally disintegrating tablet>
By tableting the composition for orally disintegrating tablets, an orally disintegrating tablets can be obtained. The orally disintegrating tablet is not particularly limited in physical properties such as hardness and disintegration as long as it is obtained by the composition for orally disintegrating tablet which is one aspect of the present invention.
口腔内崩壊錠の硬度は、充填時、輸送時及び/又はPTPシートから口腔内崩壊錠を取り出す際に、割れ、欠けなどを防ぐ観点から、好ましくは40N以上であり、より好ましくは40N〜250Nであり、更に好ましくは40N〜100Nである。硬度は、後述する実施例に記載の方法によって測定される。 The hardness of the orally disintegrating tablet is preferably 40N or more, more preferably 40N to 250N, from the viewpoint of preventing cracking, chipping, etc. during filling, transportation, and / or when the orally disintegrating tablet is taken out from the PTP sheet. It is more preferably 40N to 100N. The hardness is measured by the method described in Examples described later.
口腔内崩壊錠の崩壊性は、引張圧縮試験機を用いて口腔内崩壊錠に0.1Nの荷重を200秒間かけた際のプローブの変位量(200秒後の変位値)及び/又は崩壊速度によって評価される。 The disintegration property of the orally disintegrating tablet is the displacement amount (displacement value after 200 seconds) and / or the disintegrating speed of the probe when a load of 0.1 N is applied to the orally disintegrating tablet for 200 seconds using a tensile compression tester. Evaluated by.
口腔内崩壊錠の崩壊性は、好ましい服用性であるというためには、200秒後の変位値について、好ましくは−0.1mm〜−5.0mmであり、より好ましくは−0.4mm〜−3.5mmであり、更に好ましくは−0.6mm〜−3.0mmであり;及び/又は、崩壊速度について、好ましくは−0.5×10−2mm/s〜−5.0×10−2mm/sであり、より好ましくは−0.5×10−2mm/s〜−3.5×10−2mm/sであり、更に好ましくは−0.8×10−2mm/s〜−3.0×10−2mm/sである。口腔内崩壊錠の200秒後の変位値及び崩壊速度は、後述する実施例にて詳述される方法に従い測定される。 The disintegration property of the orally disintegrating tablet is preferably -0.1 mm to -5.0 mm, more preferably -0.4 mm to-for the displacement value after 200 seconds, in order to say that it is preferable to take. is 3.5 mm, and more preferably is at -0.6mm~-3.0mm; and / or, for disintegration rate, preferably -0.5 × 10 -2 mm / s~- 5.0 × 10 - a 2 mm / s, more preferably -0.5 × 10 -2 mm / s~- 3.5 × 10 -2 mm / s, more preferably -0.8 × 10 -2 mm / s ~ −3.0 × 10 −2 mm / s. The displacement value and disintegration rate of the orally disintegrating tablet after 200 seconds are measured according to the method detailed in Examples described later.
<口腔内崩壊錠の製造方法>
口腔内崩壊錠の製造方法は、本発明の一態様の口腔内崩壊錠用組成物を打錠することにより、口腔内崩壊錠を得る工程を含む。口腔内崩壊錠は、水溶性セルロースエーテルと、カテキンと、糖と、任意に糖アルコール及び添加物とを含む。口腔内崩壊錠は、活性成分を含むことが好ましい。
<Manufacturing method of orally disintegrating tablets>
The method for producing an orally disintegrating tablet includes a step of obtaining an orally disintegrating tablet by tableting the composition for an orally disintegrating tablet according to one aspect of the present invention. Orally disintegrating tablets include water-soluble cellulose ether, catechin, sugar, and optionally sugar alcohols and additives. The orally disintegrating tablet preferably contains an active ingredient.
打錠は、打錠機を用いて行うことができる。打錠機としては、例えば、ロータリー式打錠機、単発式打錠機などが挙げられる。打錠時の打錠圧は、錠剤硬度及び打錠障害の観点から、2kN〜40kNが好ましい。 Locking can be performed using a locking machine. Examples of the locking machine include a rotary type locking machine and a single-shot locking machine. The tableting pressure at the time of tableting is preferably 2 kN to 40 kN from the viewpoint of tablet hardness and tableting disorder.
打錠後の口腔内崩壊錠の大きさ及び質量などの製剤設計は所望のとおりに適宜設定できる。例えば、口腔内崩壊錠の径(口腔内崩壊錠の直径)は、取り扱い性及び服用性の観点から、好ましくは6mm〜12mmである。口腔内崩壊錠の質量は特に限定されず、一錠あたり、好ましくは70mg〜700mgである。 The formulation design such as the size and mass of the orally disintegrating tablet after tableting can be appropriately set as desired. For example, the diameter of the orally disintegrating tablet (the diameter of the orally disintegrating tablet) is preferably 6 mm to 12 mm from the viewpoint of handleability and ease of administration. The mass of the orally disintegrating tablet is not particularly limited, and is preferably 70 mg to 700 mg per tablet.
以下に、実施例及び比較例により本発明を更に詳細に説明するが、本発明はこれらの実施例に限定されるものではない。 Hereinafter, the present invention will be described in more detail with reference to Examples and Comparative Examples, but the present invention is not limited to these Examples.
<使用材料>
水溶性セルロースエーテルは、常法に従って製造した、ヒプロメロース(HPMC−1〜HPMC−4)及びメチルセルロース(MC−1)を用いた。使用した水溶性セルロースエーテルの物性を表1に示す。
<Material used>
As the water-soluble cellulose ether, hypromellose (HPMC-1 to HPMC-4) and methyl cellulose (MC-1) produced according to a conventional method were used. Table 1 shows the physical characteristics of the water-soluble cellulose ether used.
カテキンは、「サンフード100」(三菱ケミカルフーズ社製;エピガロカテキンガレード及びエピカテキンガレードの合計量:25質量%以上)を用いた。 As the catechin, "Sunfood 100" (manufactured by Mitsubishi Chemical Foods Co., Ltd .; total amount of epigallocatechin galley and epicatechin galade: 25% by mass or more) was used.
糖は、乳糖(「Pharmatose 200M」;DFE Pharma社製;平均粒子径:40μm)及びマルトース(「サンマルトミドリ」;株式会社林原社製;平均粒子径:49μm)を用いた。 As the sugar, lactose (“Pharmatose 200M”; manufactured by DFE Pharma; average particle size: 40 μm) and maltose (“San Marto Midori”; manufactured by Hayashibara Co., Ltd .; average particle size: 49 μm) were used.
糖アルコールは、エリスリトール(「エリスリトール50M」;物産フードサイエンス社製;平均粒子径:50μm)及びD(−)−マンニトール(富士フィルム和光純薬社製;平均粒子径:40μm)を用いた。 As the sugar alcohol, erythritol (“Erythritol 50M”; manufactured by Bussan Food Science Co., Ltd .; average particle size: 50 μm) and D (-)-mannitol (manufactured by Fuji Film Wako Pure Chemical Industries, Ltd .; average particle size: 40 μm) were used.
活性成分は、リボフラビン(「ビタミンB2」;協和ファーマケミカル社製)を用いた。 Riboflavin (“Vitamin B 2 ”; manufactured by Kyowa Pharma Chemical Co., Ltd.) was used as the active ingredient.
<物性評価>
[平均粒子径]
平均粒子径(d50)は、レーザー回折式粒度分布測定装置(「マスターサイザー3000」;Malvern社製)を用いて、Fraunhofer回折理論により、乾式法にて、分散圧1.5bar、散乱強度2%〜10%の条件で、体積基準の累積粒度分布曲線の50%累積値により測定した。
<Physical property evaluation>
[Average particle size]
The average particle size (d 50 ) is determined by a dry method using a laser diffraction type particle size distribution measuring device (“Mastersizer 3000”; manufactured by Malvern) according to the Fraunhofer diffraction theory, with a dispersion pressure of 1.5 bar and a scattering intensity of 2. It was measured by the 50% cumulative value of the volume-based cumulative particle size distribution curve under the condition of% to 10%.
[粘度]
水溶性セルロースエーテルの水分換算した乾燥物6gに対応する量を広口瓶(直径65mm;高さ120mm;体積350ml)に正確に量り、98℃の熱湯を加えて300.0gとした。広口瓶に蓋をした後、撹拌機を用いて均一な分散液となるまで350rpm〜500rpmで20分間撹拌した。その後、0℃〜5℃の水浴中で40分間撹拌して水溶性セルロースエーテルを溶解することにより、試料溶液として水溶性セルロースエーテルの2質量%水溶液を得た。
[viscosity]
The amount corresponding to 6 g of the water-soluble cellulose ether in terms of water content was accurately weighed in a wide-mouthed bottle (diameter 65 mm; height 120 mm; volume 350 ml), and boiling water at 98 ° C. was added to make 300.0 g. After covering the wide-mouthed bottle, the mixture was stirred with a stirrer at 350 rpm to 500 rpm for 20 minutes until a uniform dispersion was obtained. Then, the water-soluble cellulose ether was dissolved by stirring in a water bath at 0 ° C. to 5 ° C. for 40 minutes to obtain a 2% by mass aqueous solution of the water-soluble cellulose ether as a sample solution.
水溶性セルロースエーテルの2質量%水溶液の20℃における粘度を、第十七改正日本薬局方に記載の一般試験法の粘度測定方法の毛細管粘度計法に従い、ウベローデ型粘度計を用いて測定した。 The viscosity of a 2% by mass aqueous solution of water-soluble cellulose ether at 20 ° C. was measured using a Ubbelohde viscometer according to the capillary viscometer method of the viscosity measuring method of the general test method described in the 17th revised Japanese Pharmacy.
[メトキシ基含有量及びヒドロキシプロポキシ基含有量]
第十七改正日本薬局方の「ヒプロメロース」及び「メチルセルロース」の項に記載の定量法に従って測定した。
[Methoxy group content and hydroxypropoxy group content]
The measurement was performed according to the quantitative method described in the "hypromellose" and "methylcellulose" sections of the 17th revised Japanese Pharmacopoeia.
[水分]
秤量瓶に造粒物1gを秤量し、105℃に設定した乾燥機内に3時間静置させた後の重量変化率から水分量(乾燥減量)を求めることにより算出した。
[moisture]
It was calculated by weighing 1 g of the granulated product in a weighing bottle and determining the water content (drying weight loss) from the weight change rate after allowing it to stand in a dryer set at 105 ° C. for 3 hours.
[錠剤の硬度]
下記のとおりに製造した口腔内崩壊錠について、以下の測定条件により、錠剤硬度計(「TBH125」;ERWEKA株式会社製)を用いて、錠剤の直径方向に下記の等速度及び等圧力で荷重をかけ、錠剤が破断したときの最大破断強度として測定した。試験数は3回とし、その平均値を錠剤の硬度とした。
[Tablet hardness]
For orally disintegrating tablets manufactured as follows, a load was applied in the diameter direction of the tablets at the following constant velocity and pressure using a tablet hardness tester (“TBH125”; manufactured by ERWEKA Co., Ltd.) under the following measurement conditions. It was measured as the maximum breaking strength when the tablet was broken. The number of tests was 3 times, and the average value was taken as the hardness of the tablet.
硬度の測定条件:
等速度:2.3mm/s
等圧力:20N/s
Hardness measurement conditions:
Constant velocity: 2.3 mm / s
Isobaric pressure: 20 N / s
[錠剤の崩壊性]
製造した口腔内崩壊錠について、引張圧縮試験機(「SDT−503NB」;今田製作所株式会社製)を用いて以下の手順により崩壊性を評価した。
[Tablet disintegration]
The disintegration of the produced orally disintegrating tablet was evaluated by the following procedure using a tensile compression tester (“SDT-503NB”; manufactured by Imada Seisakusho Co., Ltd.).
後述するとおりに製造した口腔内崩壊錠を直径95mm、深さ15mmのシャーレ中央へ置き、下記の条件にて圧縮測定を開始した。プローブ(直径:11.28mm、円筒状)が口腔内崩壊錠表面へ接触し、開始点検出荷重値に達した時間を測定開始時間として、5秒後に15mlの精製水を加えた。 The orally disintegrating tablet produced as described later was placed in the center of a petri dish having a diameter of 95 mm and a depth of 15 mm, and compression measurement was started under the following conditions. After 5 seconds, 15 ml of purified water was added with the time when the probe (diameter: 11.28 mm, cylindrical) came into contact with the surface of the orally disintegrating tablet and reached the starting point detection load value as the measurement start time.
口腔内崩壊錠は200秒間、約0.1Nの荷重が掛けられ、口腔内崩壊錠の崩壊に伴うプローブの変位量を崩壊性の指標とした。荷重が開始点検出荷重値に達した際のプローブの位置を原点として変位値が負に大きい程、その口腔内崩壊錠の崩壊性が高いことを示している。 A load of about 0.1 N was applied to the orally disintegrating tablet for 200 seconds, and the displacement amount of the probe accompanying the disintegration of the orally disintegrating tablet was used as an index of disintegration. It is shown that the larger the displacement value is negative with the position of the probe as the origin when the load reaches the start point detection load value, the higher the disintegration property of the orally disintegrating tablet.
また、得られた崩壊プロファイルから5秒当たりのプローブの変位速度(式1に基づく)を算出し、試験開始後に変位速度が−0.002以下となった点を崩壊開始点と定義し、その後に変位速度が−0.002以上となった点を崩壊終点と定義した。崩壊開始点及び崩壊終点の2点から得られる直線の傾きを崩壊速度(式2に基づく)と定義した。崩壊速度が負に大きい程、その口腔内崩壊錠の崩壊性が高いことを示している。 In addition, the displacement velocity of the probe per 5 seconds (based on Equation 1) was calculated from the obtained decay profile, and the point where the displacement velocity became -0.002 or less after the start of the test was defined as the collapse start point, and then. The point where the displacement velocity was -0.002 or more was defined as the collapse end point. The slope of a straight line obtained from the two points of the collapse start point and the collapse end point was defined as the collapse rate (based on Equation 2). The larger the disintegration rate, the higher the disintegration property of the orally disintegrating tablet.
具体的には、式1に従って0(測定開始)〜5秒間、1〜6秒間、2〜7秒間といったように5秒間におけるプローブの変化量(変位値)を順々に求め、変位速度を順々に算出していき、崩壊開始点及び崩壊終点を求め、式2に従って崩壊速度を算出した。 Specifically, according to Equation 1, the amount of change (displacement value) of the probe in 5 seconds such as 0 (measurement start) to 5 seconds, 1 to 6 seconds, and 2 to 7 seconds is sequentially obtained, and the displacement speed is determined in order. The collapse start point and the collapse end point were calculated individually, and the collapse rate was calculated according to Equation 2.
(式1)
変位速度(mm/s)=5秒間におけるプローブの変化量(変位値)/5
(式2)
崩壊速度(mm/s)=(崩壊終点の変位値−崩壊開始点の変位値)/(崩壊終点の時間−崩壊開始点の時間)
(Equation 1)
Displacement speed (mm / s) = amount of change (displacement value) of probe in 5 seconds / 5
(Equation 2)
Collapse velocity (mm / s) = (displacement value at the end point of collapse-displacement value at the start point of collapse) / (time at the end point of collapse-time at the start point of collapse)
SDT−503NB型引張圧縮試験機の測定条件:
開始点検出:0.1N
荷重:0.1N
荷重幅:0.05〜0.15N
試験速度:5.0mm/min
維持速度:10mm/min
調整速度:1.0mm/min
切替荷重:0.05N
Measurement conditions of SDT-503NB type tensile compression tester:
Start point detection: 0.1N
Load: 0.1N
Load width: 0.05 to 0.15N
Test speed: 5.0 mm / min
Maintenance speed: 10 mm / min
Adjustment speed: 1.0 mm / min
Switching load: 0.05N
<口腔内崩壊錠用組成物及び口腔内崩壊錠の製造>
[実施例1]
HPMC−1、カテキン及び乳糖を表2に記載の質量比となるように秤量及び混合し、口腔内崩壊錠用組成物を製造した。
<Manufacturing of composition for orally disintegrating tablets and orally disintegrating tablets>
[Example 1]
HPMC-1, catechin and lactose were weighed and mixed so as to have the mass ratios shown in Table 2 to prepare a composition for orally disintegrating tablets.
製造した口腔内崩壊錠用組成物350mgを、錠剤成形機(「HAND TAB−200」;市橋精機株式会社製)を用いて、打錠圧15kNで打錠し、1錠の直径が10mmであり、曲率半径が14.0mmであり、及び錠剤質量が350mgである口腔内崩壊錠を製造した。 The produced composition for orally disintegrating tablets 350 mg was tableted using a tablet molding machine (“HAND TAB-200”; manufactured by Ichihashi Seiki Co., Ltd.) at a tableting pressure of 15 kN, and the diameter of one tablet was 10 mm. An orally disintegrating tablet having a radius of curvature of 14.0 mm and a tablet mass of 350 mg was produced.
[実施例2]
糖として、乳糖に代えてマルトースを用いた以外は実施例1と同様の方法で口腔内崩壊錠用組成物を製造した。
[Example 2]
A composition for an orally disintegrating tablet was produced in the same manner as in Example 1 except that maltose was used as the sugar instead of lactose.
製造した口腔内崩壊錠用組成物350mgを、錠剤成形機(「HAND TAB−200」;市橋精機株式会社製)を用いて、実施例1と同程度の錠剤硬度となるように打錠圧1.0kNで打錠して口腔内崩壊錠を製造した。 Using a tablet molding machine (“HAND TAB-200”; manufactured by Ichihashi Seiki Co., Ltd.), 350 mg of the produced composition for orally disintegrating tablets was tableted with a tableting pressure of 1 so as to have the same tablet hardness as in Example 1. Orally disintegrating tablets were produced by tableting at 0.0 kN.
[実施例3]
水溶性セルロースエーテルとして、HPMC−1に代えてHPMC−2を用いた以外は実施例1と同様の方法で口腔内崩壊錠用組成物及び口腔内崩壊錠を製造した。
[Example 3]
A composition for an orally disintegrating tablet and an orally disintegrating tablet were produced in the same manner as in Example 1 except that HPMC-2 was used as the water-soluble cellulose ether instead of HPMC-1.
[実施例4]
HPMC−1、カテキン、乳糖及びエリスリトールを表2に記載の質量比となるように秤量及び混合し、口腔内崩壊錠用組成物を製造した。製造した口腔内崩壊錠用組成物を用いて、実施例1と同様の方法で口腔内崩壊錠を製造した。
[Example 4]
HPMC-1, catechin, lactose and erythritol were weighed and mixed so as to have the mass ratios shown in Table 2 to prepare a composition for orally disintegrating tablets. Using the produced composition for orally disintegrating tablets, orally disintegrating tablets were produced in the same manner as in Example 1.
[実施例5]
HPMC−1、カテキン、マルトース及びエリスリトールを表2に記載の質量比となるように秤量及び混合し、口腔内崩壊錠用組成物を製造した。
[Example 5]
HPMC-1, catechin, maltose and erythritol were weighed and mixed so as to have the mass ratios shown in Table 2 to prepare a composition for orally disintegrating tablets.
製造した口腔内崩壊錠用組成物350mgを、錠剤成形機(「HAND TAB−200」;市橋精機株式会社製)を用いて、実施例2と同程度の錠剤硬度となるように打錠圧2.5kNで打錠して口腔内崩壊錠を製造した。 Using a tablet molding machine (“HAND TAB-200”; manufactured by Ichihashi Seiki Co., Ltd.), 350 mg of the produced composition for orally disintegrating tablets was tableted with a tableting pressure of 2 so as to have the same tablet hardness as in Example 2. Orally disintegrating tablets were produced by tableting at .5 kN.
[実施例6]
HPMC−1とカテキンとの質量比(水溶性セルロースエーテル/カテキン)が2.3となるようにした以外は、実施例4と同様の方法で口腔内崩壊錠用組成物及び口腔内崩壊錠を製造した。
[Example 6]
The composition for orally disintegrating tablets and the orally disintegrating tablets were prepared in the same manner as in Example 4 except that the mass ratio of HPMC-1 to catechin (water-soluble cellulose ether / catechin) was 2.3. Manufactured.
[実施例7]
HPMC−1とカテキンとの質量比(水溶性セルロースエーテル/カテキン)が1.0となるようにした以外は、実施例4と同様の方法で口腔内崩壊錠用組成物及び口腔内崩壊錠を製造した。
[Example 7]
The composition for orally disintegrating tablets and the orally disintegrating tablets were prepared in the same manner as in Example 4 except that the mass ratio of HPMC-1 to catechin (water-soluble cellulose ether / catechin) was 1.0. Manufactured.
[実施例8]
水溶性セルロースエーテルとして、HPMC−1に代えてHPMC−2を用いた以外は実施例4と同様の方法で口腔内崩壊錠用組成物及び口腔内崩壊錠を製造した。
[Example 8]
A composition for an orally disintegrating tablet and an orally disintegrating tablet were produced in the same manner as in Example 4 except that HPMC-2 was used as the water-soluble cellulose ether instead of HPMC-1.
[実施例9]
糖アルコールとして、エリスリトールに代えてD−マンニトールを用いた以外は実施例8と同様の方法で口腔内崩壊錠用組成物及び口腔内崩壊錠を製造した。
[Example 9]
A composition for an orally disintegrating tablet and an orally disintegrating tablet were produced in the same manner as in Example 8 except that D-mannitol was used as the sugar alcohol instead of erythritol.
[実施例10]
水溶性セルロースエーテルとして、HPMC−1に代えてHPMC−3を用いた以外は実施例4と同様の方法で口腔内崩壊錠用組成物及び口腔内崩壊錠を製造した。
[Example 10]
A composition for an orally disintegrating tablet and an orally disintegrating tablet were produced in the same manner as in Example 4 except that HPMC-3 was used as the water-soluble cellulose ether instead of HPMC-1.
[実施例11]
水溶性セルロースエーテルとして、HPMC−1に代えてMC−1を用いた以外は実施例4と同様の方法で口腔内崩壊錠用組成物及び口腔内崩壊錠を製造した。
[Example 11]
A composition for an orally disintegrating tablet and an orally disintegrating tablet were produced in the same manner as in Example 4 except that MC-1 was used instead of HPMC-1 as the water-soluble cellulose ether.
[実施例12]
HPMC−4(7.6g)、カテキン(1.6g)、乳糖(160g)及びエリスリトール(30.8g)を流動層造粒装置に仕込み、エタノールと精製水との混合液(エタノール/精製水=7/3(質量比)、300g)を用いて下記の条件で造粒を行い、平均粒子径が173μmの造粒物として口腔内崩壊錠用組成物を得た。なお、造粒物の水分量(乾燥減量)は0.5質量%であった。
[Example 12]
HPMC-4 (7.6 g), catechin (1.6 g), lactose (160 g) and erythritol (30.8 g) were charged into a fluidized layer granulator, and a mixed solution of ethanol and purified water (ethanol / purified water =). Granulation was carried out under the following conditions using 7/3 (mass ratio), 300 g) to obtain a composition for orally disintegrating tablets as a granulated product having an average particle diameter of 173 μm. The water content (dry weight loss) of the granulated product was 0.5% by mass.
得られた造粒物(口腔内崩壊錠用組成物)を用いて実施例1と同様に口腔内崩壊錠を製造した。 Using the obtained granulated product (composition for orally disintegrating tablet), an orally disintegrating tablet was produced in the same manner as in Example 1.
<使用装置>
流動層造粒機「フローコーター FZ−LABO」(フロイント産業株式会社)
<造粒条件>
吸気温度:60℃
排気温度:27〜32℃
流動エアー量:45L/min
スプレー速度:10〜12g/min
スプレーエアー圧:0.10MPa
<Device used>
Fluidized bed granulator "Flow coater FZ-LABO" (Freund Sangyo Co., Ltd.)
<Granulation conditions>
Intake temperature: 60 ° C
Exhaust temperature: 27-32 ° C
Flowing air amount: 45L / min
Spray speed: 10-12g / min
Spray air pressure: 0.10 MPa
[実施例13]
HPMC−4(5.3g)及びカテキン(1.1g)を用いて、下記条件にて加熱溶融押出を行うことにより押出物を得た。押出物は「ワンダーブレンダー」(大阪ケミカル株式会社)を用いて3秒間かけて粉砕し、平均粒子径が143μmの粉砕物を回収した。得られた粉砕物(2g)、乳糖(34.8g)及びエリスリトール(6.7g)を表2に記載の質量比となるように混合し、口腔内崩壊錠用組成物を製造した。
[Example 13]
An extruded product was obtained by heat melt extrusion using HPMC-4 (5.3 g) and catechin (1.1 g) under the following conditions. The extruded product was pulverized using "Wonder Blender" (Osaka Chemical Co., Ltd.) for 3 seconds, and the pulverized product having an average particle size of 143 μm was recovered. The obtained pulverized product (2 g), lactose (34.8 g) and erythritol (6.7 g) were mixed so as to have the mass ratios shown in Table 2 to prepare an orally disintegrating tablet composition.
製造した口腔内崩壊錠用組成物を用いて、実施例1と同様に口腔内崩壊錠を製造した。 Using the produced composition for orally disintegrating tablets, an orally disintegrating tablet was produced in the same manner as in Example 1.
<使用装置>
コンパウンディングエクストルーダー「HAAKE MiniLab II」(サーモフィッシャーサイエンティフィック株式会社製)
<押出条件>
バレル温度:180℃
スクリュー回転数:70rpm
投入時間:5min
循環時間:5min
<Device used>
Compounding extruder "HAAKE MiniLab II" (manufactured by Thermo Fisher Scientific Co., Ltd.)
<Extrusion conditions>
Barrel temperature: 180 ° C
Screw rotation speed: 70 rpm
Input time: 5 min
Circulation time: 5 min
[実施例14]
HPMC−2、カテキン、乳糖及びエリスリトール、更に活性成分としてリボフラビン(VB2)を加えて、表2に記載の質量比となるように秤量及び混合し、口腔内崩壊錠用組成物を製造した。
[Example 14]
HPMC-2, catechin, lactose and erythritol, and riboflavin (VB2) as an active ingredient were added and weighed and mixed so as to have the mass ratios shown in Table 2 to prepare a composition for orally disintegrating tablets.
製造した口腔内崩壊錠用組成物350mgを、錠剤成形機(「HAND TAB−200」;市橋精機株式会社製)を用いて、実施例3と同程度の錠剤硬度となるように打錠圧7.0kNで打錠して口腔内崩壊錠を製造した。 Using a tablet molding machine (“HAND TAB-200”; manufactured by Ichihashi Seiki Co., Ltd.), 350 mg of the produced composition for orally disintegrating tablets was tableted with a tableting pressure of 7 so as to have the same tablet hardness as in Example 3. Orally disintegrating tablets were produced by tableting at 0.0 kN.
[比較例1]
カテキンを加えずに、HPMC−1及び乳糖を表2に記載の質量比となるように秤量及び混合し、錠剤用組成物を製造した。製造した錠剤用組成物を用いて実施例1と同様の方法で錠剤を得た。
[Comparative Example 1]
HPMC-1 and lactose were weighed and mixed so as to have the mass ratios shown in Table 2 without adding catechin to prepare a tablet composition. Tablets were obtained in the same manner as in Example 1 using the produced tablet composition.
なお、比較例1においては錠剤の崩壊が起きず、変位速度(mm/s)が−0.002以下になることがなかったため、崩壊速度が算出できなかった。 In Comparative Example 1, the disintegration rate could not be calculated because the tablets did not disintegrate and the displacement rate (mm / s) did not become −0.002 or less.
[比較例2]
水溶性セルロースエーテルを加えずに、カテキン及び乳糖を表2に記載の質量比となるように秤量及び混合し、錠剤用組成物を製造した。製造した錠剤用組成物を用いて実施例1と同様の方法で錠剤を得た。
[Comparative Example 2]
A tablet composition was prepared by weighing and mixing catechin and lactose so as to have the mass ratios shown in Table 2 without adding water-soluble cellulose ether. Tablets were obtained in the same manner as in Example 1 using the produced tablet composition.
なお、比較例2においては錠剤の崩壊が起きず、変位速度(mm/s)が−0.002以下になることがなかったため、崩壊速度が算出できなかった。 In Comparative Example 2, the disintegration rate could not be calculated because the tablets did not disintegrate and the displacement rate (mm / s) did not become −0.002 or less.
[比較例3]
糖を加えずに、HPMC−1及びカテキンを表2に記載の質量比となるように秤量及び混合し、錠剤用組成物を製造した。
[Comparative Example 3]
HPMC-1 and catechin were weighed and mixed in the mass ratios shown in Table 2 without adding sugar to prepare a tablet composition.
製造した錠剤用組成物350mgを、錠剤成形機(「HAND TAB−200」;市橋精機株式会社製)を用いて、実施例1と同程度の錠剤硬度となるように打錠圧2.0kNで打錠して錠剤を製造した。 Using a tablet molding machine (“HAND TAB-200”; manufactured by Ichihashi Seiki Co., Ltd.), 350 mg of the produced tablet composition was used at a tableting pressure of 2.0 kN so as to have the same tablet hardness as in Example 1. Tableting was performed to produce tablets.
なお、比較例3においては錠剤の崩壊が起きず、変位速度(mm/s)が−0.002以下になることがなかったため、崩壊速度が算出できなかった。 In Comparative Example 3, the disintegration rate could not be calculated because the tablets did not disintegrate and the displacement rate (mm / s) did not become −0.002 or less.
<口腔内崩壊錠の評価>
実施例1と比較例1〜3との比較により、水溶性セルロースエーテルと、カテキンと、糖とを含む口腔内崩壊錠用組成物から製造した口腔内崩壊錠は、十分な硬度及び優れた崩壊性を示すことが知見された。また、実施例1及び実施例2の結果から、乳糖、マルトースといった糖の種類に依らずに、十分な硬度及び優れた崩壊性を示す口腔内崩壊錠が得られることが確認された。
<Evaluation of orally disintegrating tablets>
By comparing Example 1 and Comparative Examples 1 to 3, the orally disintegrating tablet produced from the composition for orally disintegrating tablet containing water-soluble cellulose ether, catechin, and sugar had sufficient hardness and excellent disintegration. It was found to show sex. Further, from the results of Examples 1 and 2, it was confirmed that an orally disintegrating tablet showing sufficient hardness and excellent disintegration property can be obtained regardless of the type of sugar such as lactose and maltose.
実施例1及び実施例3の結果より、乾式混合により口腔内崩壊錠用組成物を製造する場合においては、用いる水溶性セルロースエーテルの平均粒子径が大きい程、得られる口腔内崩壊錠の崩壊性が優れることが知見された。 From the results of Examples 1 and 3, when the composition for orally disintegrating tablets is produced by dry mixing, the larger the average particle size of the water-soluble cellulose ether used, the more disintegrating the orally disintegrating tablets obtained. Was found to be excellent.
実施例1及び実施例4、並びに実施例2及び実施例5の結果より、口腔内崩壊錠用組成物が糖アルコールを含む場合において、より崩壊性に優れる口腔内崩壊錠が得られることが知見された。 From the results of Examples 1 and 4, and Examples 2 and 5, it was found that when the composition for an orally disintegrating tablet contains a sugar alcohol, an orally disintegrating tablet having more excellent disintegration property can be obtained. Was done.
実施例4、実施例6及び実施例7の結果より、口腔内崩壊錠用組成物におけるカテキンに対する水溶性セルロースエーテルの質量比が高まると、得られる口腔内崩壊錠はより硬度及び崩壊性に優れることが知見された。 From the results of Examples 4, 6 and 7, when the mass ratio of the water-soluble cellulose ether to catechin in the composition for orally disintegrating tablets is increased, the obtained orally disintegrating tablets are more excellent in hardness and disintegration. It was found that.
実施例4及び実施例8の結果より、乾式混合により糖アルコールを含む口腔内崩壊錠用組成物を製造する場合は、水溶性セルロースエーテルの平均粒子径が大きい程、得られる口腔内崩壊錠は崩壊性に優れることが知見された。 From the results of Examples 4 and 8, when producing a composition for an orally disintegrating tablet containing a sugar alcohol by dry mixing, the larger the average particle size of the water-soluble cellulose ether, the more the obtained orally disintegrating tablet It was found to be excellent in disintegration.
実施例8及び実施例9の結果より、エリスリトール、D−マンニトールといった糖アルコールの種類に依らずに、十分な硬度及び優れた崩壊性を示す口腔内崩壊錠が得られることが確認された。 From the results of Examples 8 and 9, it was confirmed that an orally disintegrating tablet exhibiting sufficient hardness and excellent disintegration property could be obtained regardless of the type of sugar alcohol such as erythritol and D-mannitol.
実施例4、実施例10及び実施例11の結果より、種々の粒子径のHPMC、MCといった水溶性セルロースエーテルの種類に依らずに、十分な硬度及び優れた崩壊性を示す口腔内崩壊錠が得られることが確認された。 From the results of Examples 4, 10 and 11, it is possible to obtain an orally disintegrating tablet that exhibits sufficient hardness and excellent disintegration property regardless of the type of water-soluble cellulose ether such as HPMC and MC having various particle sizes. It was confirmed that it could be obtained.
実施例10、実施例12及び実施例13の結果より、乾式混合、造粒、加熱溶融押出といった口腔内崩壊錠用組成物の製造方法に依らずに、十分な硬度及び優れた崩壊性を示す口腔内崩壊錠が得られることが確認された。ただし、口腔内崩壊錠用組成物の製造方法により、得られる口腔内崩壊錠の崩壊挙動が異なるなどの理由により、加熱溶融押出により200秒後の変位値及び崩壊速度が優れる口腔内崩壊錠が得られることが知見された。 From the results of Example 10, Example 12, and Example 13, sufficient hardness and excellent disintegration property are exhibited regardless of the method for producing the composition for orally disintegrating tablets such as dry mixing, granulation, and heat melt extrusion. It was confirmed that an orally disintegrating tablet was obtained. However, due to the fact that the disintegration behavior of the obtained orally disintegrating tablet differs depending on the method for producing the composition for the orally disintegrating tablet, the orally disintegrating tablet having an excellent displacement value and disintegration rate after 200 seconds by heat melt extrusion can be obtained. It was found that it was obtained.
実施例3及び実施例14の結果より、活性成分を含む場合においても、十分な硬度及び優れた崩壊性を示す口腔内崩壊錠が得られることが確認された。 From the results of Examples 3 and 14, it was confirmed that an orally disintegrating tablet showing sufficient hardness and excellent disintegration property can be obtained even when the active ingredient is contained.
本発明によれば、複雑な工程を採用することなく、汎用的かつ工業的規模で、十分な硬度を有し、かつ優れた崩壊性を示す口腔内崩壊錠を製造することができる。
According to the present invention, it is possible to produce an orally disintegrating tablet having sufficient hardness and exhibiting excellent disintegration property on a general-purpose and industrial scale without adopting a complicated process.
Claims (11)
前記押出物を粉砕することにより、粉砕物を得る工程と、
前記粉砕物と、糖を含む原料とを混合することにより、水溶性セルロースエーテルと、カテキンと、糖とを含む口腔内崩壊錠用組成物を得る工程
とを含む口腔内崩壊錠用組成物の製造方法。 A step of obtaining an extruded product containing water-soluble cellulose ether and catechin by heating, melting and extruding a powder raw material containing water-soluble cellulose ether and catechin.
A step of obtaining a pulverized product by pulverizing the extruded product, and
A composition for an orally disintegrating tablet, which comprises a step of obtaining a composition for an orally disintegrating tablet containing the water-soluble cellulose ether, catechin, and sugar by mixing the pulverized product with a raw material containing sugar. Production method.
A method for producing an orally disintegrating tablet, which comprises a step of obtaining an orally disintegrating tablet by tableting the composition for an orally disintegrating tablet according to any one of claims 7 to 10.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019149696A JP7129957B2 (en) | 2019-08-19 | 2019-08-19 | Orally disintegrating tablet composition, method for producing the same, and orally disintegrating tablet using the same and method for producing the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019149696A JP7129957B2 (en) | 2019-08-19 | 2019-08-19 | Orally disintegrating tablet composition, method for producing the same, and orally disintegrating tablet using the same and method for producing the same |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021031404A true JP2021031404A (en) | 2021-03-01 |
JP7129957B2 JP7129957B2 (en) | 2022-09-02 |
Family
ID=74675347
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019149696A Active JP7129957B2 (en) | 2019-08-19 | 2019-08-19 | Orally disintegrating tablet composition, method for producing the same, and orally disintegrating tablet using the same and method for producing the same |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP7129957B2 (en) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001322927A (en) * | 2000-05-12 | 2001-11-20 | Shin Etsu Chem Co Ltd | Solid preparation including hydroxypropyl cellulose of low substitution degree and method for preparation of the same |
JP2005132788A (en) * | 2003-10-31 | 2005-05-26 | Lion Corp | Orally disintegrable tablet |
JP2011518792A (en) * | 2008-04-24 | 2011-06-30 | インデナ エッセ ピ ア | Oral infection treatment and prevention composition |
CN103356811A (en) * | 2013-06-18 | 2013-10-23 | 荆州市荆康生物科技有限公司 | Chewable tables for oral cavities as well as preparation method and application thereof |
WO2014038593A2 (en) * | 2012-09-05 | 2014-03-13 | テイカ製薬株式会社 | Granulated material for tablet that rapidly disintegrates in mouth |
JP2015168643A (en) * | 2014-03-06 | 2015-09-28 | 静岡県公立大学法人 | Orally disintegrating tablet containing high amount of herbal medicine powder, and method for producing the same |
JP2016501944A (en) * | 2012-12-11 | 2016-01-21 | サムスン ファイン ケミカルズ カンパニー リミテッドSamsungfine Chemicals Co.,Ltd. | COMPOSITION FOR COMPOSITION FORMING, COMPOSITE FORMED FROM THE SAME, AND COMPOSITION FOR ORAL INTAKE USING SAME |
-
2019
- 2019-08-19 JP JP2019149696A patent/JP7129957B2/en active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001322927A (en) * | 2000-05-12 | 2001-11-20 | Shin Etsu Chem Co Ltd | Solid preparation including hydroxypropyl cellulose of low substitution degree and method for preparation of the same |
JP2005132788A (en) * | 2003-10-31 | 2005-05-26 | Lion Corp | Orally disintegrable tablet |
JP2011518792A (en) * | 2008-04-24 | 2011-06-30 | インデナ エッセ ピ ア | Oral infection treatment and prevention composition |
WO2014038593A2 (en) * | 2012-09-05 | 2014-03-13 | テイカ製薬株式会社 | Granulated material for tablet that rapidly disintegrates in mouth |
JP2016501944A (en) * | 2012-12-11 | 2016-01-21 | サムスン ファイン ケミカルズ カンパニー リミテッドSamsungfine Chemicals Co.,Ltd. | COMPOSITION FOR COMPOSITION FORMING, COMPOSITE FORMED FROM THE SAME, AND COMPOSITION FOR ORAL INTAKE USING SAME |
CN103356811A (en) * | 2013-06-18 | 2013-10-23 | 荆州市荆康生物科技有限公司 | Chewable tables for oral cavities as well as preparation method and application thereof |
JP2015168643A (en) * | 2014-03-06 | 2015-09-28 | 静岡県公立大学法人 | Orally disintegrating tablet containing high amount of herbal medicine powder, and method for producing the same |
Non-Patent Citations (3)
Title |
---|
NIPPON NOGEIKAGAKU KAISHI, vol. Vol.69(9), JPN6022025960, 1995, pages 1202 - 1205, ISSN: 0004811971 * |
家庭薬研究, vol. 32, JPN6022025957, 2013, pages 42 - 49, ISSN: 0004839712 * |
家庭薬研究, vol. 35, JPN6022025958, 2016, pages 39 - 48, ISSN: 0004839713 * |
Also Published As
Publication number | Publication date |
---|---|
JP7129957B2 (en) | 2022-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8951636B2 (en) | Composite particles which contain both cellulose and inorganic compound | |
JP6216074B2 (en) | Fine cellulose powder | |
US10426838B2 (en) | Composite particles including cellulose, inorganic compound, and hydroxypropyl cellulose | |
JP2009185083A (en) | Stable tablet containing droxidopa | |
JP6138635B2 (en) | Cellulosic core particles and method for producing the same | |
AU2015251692A1 (en) | Disintegrating particle composition including microfibrous cellulose | |
KR102377914B1 (en) | Disintegrative particle composition including pulverized lactose or granulated lactose | |
CA3124534C (en) | Cellulose powder, use thereof, and tablets | |
JP7145121B2 (en) | Tablet manufacturing method | |
JP2015218322A (en) | Fine starch particle and production method thereof | |
JP6104038B2 (en) | Composite composition of crystalline cellulose | |
JP2013032351A (en) | Herbal medicine or crude medicine formulation and method for producing the same | |
JP7129957B2 (en) | Orally disintegrating tablet composition, method for producing the same, and orally disintegrating tablet using the same and method for producing the same | |
JP7414668B2 (en) | Granules and solid preparations containing polyvinyl alcohol | |
JP2018083923A (en) | Cellulose dispersion, method for producing cellulose dispersion, molded body composition, molded body, and method for producing molded body composition | |
JP6983139B2 (en) | Compositions for solid formulations, solid formulations and methods for producing them | |
JP6273151B2 (en) | Cellulosic core particles and method for producing the same | |
JP6744517B1 (en) | Cellulose composition, tablet and orally disintegrating tablet | |
US10980747B2 (en) | Composition for solid preparation, solid preparation, and method for producing the same | |
TW201639598A (en) | Delayed disintegrating particulate composition | |
JP2022139962A (en) | Granules, method for producing granules, and tablet | |
JP2020094023A (en) | Excipient granules, tablet and method for producing tablet | |
KR20170105421A (en) | Solid preparation containing alkyl cellulose and method for producing the same | |
JP2010095490A (en) | Method for producing tablet |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210825 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220519 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220628 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220719 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220802 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220823 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7129957 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |